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Use of a generalized linear mixed model with a binary outcome and logit link function is
proposed to generate trajectories of the probability of use of novel medical procedures. It is hy-
pothesized that the shape of these innovation adoption trajectories vary by institution and region
and are influenced by patient, institutional, and geographic factors. The example of the adoption of
sentinel lymph node biopsy in the treatment of early stage breast cancer is used to demonstrate the
model’s utility and improvement over those typically used in registry and claims-based research.
Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 1999 to 2007 was used
as the basis for these model-based trajectories. Fixed effects included patient, institution, and re-
gional variables including a cubic polynomial of time for each region. Random effects were at
the institution level and included a cubic polynomial of time. Results indicated a better fit of the
multilevel model with a polynomial of time in comparison to standard models and that patient,
institutional, and geographic factors influence the shape of the adoption trajectory of this novel
medical procedure.
Additionally, an evidence-based medical implementation index (EMII) was developed and
tested using sentinel node biopsy adoption trends. Data were analyzed in aggregate and at the
institution level. A single summary metric, based upon the area under the curve, was derived to
quantify the pattern of adoption ranging from 0-100, with higher scores reflecting earlier adoption.
The EMII was compared between SEER regions and between institutions. Differences in adoption
patterns were found for SEER regions and institutions (p < .001 for each effect). For SEER re-
gions (n=15) the SLNB EMII range was 33 (New Mexico) to 66 (Seattle). For all institutions: n =
720, range = 4 - 87, mean = 46, S.D. = 20, bell-shaped distribution.
iii
Finally, four estimation techniques for the random effects parameters were compared to maxi-
mum likelihood using quadrature based estimates, two types of pseudo-likelihood (PL), and jack-
knifed estimates based on these. The estimates were compared via D-, A-, and E-efficiency. Re-
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1.1.1 Measuring Quality of Cancer Care
Quality of care in the treatment of cancer is an important issue and awareness has been height-
ened ever since the Institute of Medicine released its recommendations in Ensuring Quality Can-
cer Care (39). One of the IOM’s recommendations of primary importance to this work is to
“Measure and monitor the quality of care using a core set of quality measures.” Other recommen-
dations included; “Services for the un- and underinsured should be enhanced to ensure entry to,
and equitable treatment with, the cancer care system”, “Studies are needed to find out why specific
segments of the population ... do not receive appropriate cancer care”, and “Cancer care quality
measures should be used to hold providers ... accountable for demonstrating that they provide and
improve quality of care.” While the first and last call explicitly for a set of metrics, the other two
implicitly require metrics in order to be achieved. The focus of this work is the research used to
generate the metrics that are used to measure, and ultimately improve, quality of medical care for
breast cancer patients.
One indication that quality care is being provided is the use of new evidence-based procedures.
One such procedure used in early stage breast cancer lymph node staging is Sentinel Lymph Node
Biopsy (SLNB), originally called sentinel lymphadenectomy (20). It is being used in place of
Axillary LymphNode Dissection (ALND) in some cases when appropriate (20; 8; 15; 19), although
seemingly with disparities for at risk groups (22; 35; 11; 45; 9; 44). In section 1.1.2 we describe
the procedures.
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1.1.2 Lymph Node Staging Procedures for Breast Cancer Treatment
Axillary Lymph Node Dissection (ALND)
ALND involves the removal of all level one and two ipsilateral axillary lymph nodes. It is an
extensive procedure and associated morbidities include, lymphedema, nerve paresthesias, axillary
seromas, and infections. Its primary purpose is to provide pathological nodal staging information.
It also serves the function of removing any metastatic tissue that is involved with the axillary lymph
nodes.
Figure 1.1: Sentinel lymph node biopsy procedure.
Sentinel Lymph Node Biopsy (SLNB)
SLNB is a less invasive procedure than ALND, where a few lymph nodes are removed, typi-
cally 1 to 3, and interoperatively assessed for metastatic involvement (8; 24). A standard version
of the procedure during the time period of this study started with injecting a blue dye and a ra-
dioactive tracer near the site of the tumor (36). After some time has passed both visual inspection
and a Geiger counter are used to determine which lymph node(s) the lymph near the tumor drains
to. These are excised and assessed for metastatic involvement. If it is determined that there is in-
volvement then the next node in the lymph chain is excised and examined. Using this information
it can then be determined whether to perform a completion ALND.
2
SLNB as Standard of Care for Early Stage Breast Cancer Treatment
Up through the late 1990’s the standard practice had been to perform ALND for lymph node
staging in cases of early stage breast cancer. With the advent of SLNB in the mid 1990’s and a
growing body of evidence that it was equivalent to ALND in outcomes for pathologically node
negative cases it became the standard of care (62; 13; 52; 14; 41; 54; 55; 61; 56). Medicare started
reimbursing its use in 1999 while it was still in clinical trials since early evidence suggested it was
a preferred treatment option in many cases. With the conclusion of the clinical trials SLNB became
the documented standard of care for lymphatic staging of early stage breast cancer (26).
In the following section the data source for modeling the use of SLNB, SEER-Medicare cancer
registry and claims data, is described and reviewed.
1.1.3 SEER-Medicare: Combined Cancer Registry and Medicare Claims data
SEER-Medicare data is a rich data source for treatment and outcomes of cancer in the United
States but is rather complex. It is a joining of cancer registry data and the associated Medicare
data for individuals that have Medicare coverage. It has been described extensively elsewhere,
particularly in a supplement to Medical Care in 2002 (59; 4; 25; 48). What follows in a basic
description of each of the components starting with the cancer registry data and how it’s collected.
SEER Cancer Registry Program
According to information provided during the National Cancer Institute’s SEER-Medicare data
training workshop in March 2010 (60), the Surveillance, Epidemiology, and End Results (SEER)
program contracts with state health programs and universities to operate incident cancer registries
in geographic regions around the United States of America. Currently the registries cover about
26% of the US population. The 17 registries are each headed by a different investigator and each
registry works differently. They do however use a standardized reporting system for data transmis-
sion to NCI.
It should be noted that the program is for the most part facility based and thus information for
services provided in a physician’s office might be missing or incomplete. It should also be noted
3
that for many variables there is a hierarchical structure, that is, some values supersede other values
even though both are true e.g. the maximum value is reported. The types of data included are,
diagnostic, staging, treatment, and limited demographics.
Registry data can come from a variety of sources but a case is first identified via a report from
a service provider where a cancer diagnosis was made, an autopsy report, or from a death certifi-
cate submitted to the cancer registry for the geographical region where the entity is located. In
SEER-Medicaid research it is a standard practice to exclude those cases that were only identified
via autopsy or death certificate. Thus the reporting sources include at least one of; a Hospital Inpa-
tient/Outpatient or Clinic, a Laboratory (Hospital or Private), a Physician’s Office/Private Medical
Practitioner, or a Nursing/Convalescent Home/Hospice.
There are a variety of missing data issues for SEER data. Registries don’t capture 100% of all
incident cases, although the expectation is at least 98%. SEER missing data is more likely to have
come from patients who were primarily treated at physician’s offices (rather than at a hospital or
clinic). Pathological staging data ‘overwrites’ clinical staging data and we don’t know if this has
happened or not for breast cancer (prostate cancer has separate clinical staging variables). Only
94% of the cases aged 65 or older link to Medicare data and it is unknown if this is differential,
but assumed not. Unlinked cases are not included in SEER-Medicare data. Changes in coding
systems over time have led to some staging and treatment information being collected during some
time frames but not others (or defined somewhat differently). Race data categories depend on time
period, SEER race data however is considered better than Medicare race data. Missing/unknown
categories for some SEER variables during analysis behave more like a separate level (or are sim-
ilar to another level) rather than seeming to come from the other levels proportionally. Six months
of 2005 data for Louisiana are somewhat sparse due to severe storms and an indicator variable flags
this time period. There were four new SEER registries in 2000, there is no prior data for them.
Next we consider the Medicare data that is provided by NCI in their release of SEER-Medicare
data.
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Medicare data as Provided by the SEER-Medicare Program
Medicare data used in studies of SLNB consists of eligibility, inpatient stay, outpatient service,
physician service, and durable medical equipment (which includes some cancer medications) in-
formation. Eligible individuals include qualifying individuals age 65 or greater, those with end
stage renal disease, and certain people with disabilities. Note that this is administrative (billing)
data for services that are paid for based on Medicare policy in effect at the time of service. This
has implications for completeness, particularly for procedures not covered at the time of service.
The pertinent information is obtained from four files: the hospital inpatient stay file (MEDPAR),
which has one record per hospital stay, the hospital outpatient claims file (OUTSAF), which has
one record per billable item, the non-hospital provider claims file (NCH), which has one record per
billable item, and the durable medical equipment file (DME), which includes cancer medications.
Medicare data also has its share of missing data issues. Census data sometimes is missing,
and the usual strategy is to use zip code based data in this case. There are still a (very small)
number of missing after this strategy is employed although. Physicians tend to be erratic in billing
for services they know Medicare won’t pay for, so for uncovered services there will be ‘missing’
claims data. Similarly some services are ‘bundled’ with others and only the code for the more
extensive procedure is provided. One needs to be familiar with Medicare policy during time period
of interest and during some years the location of interest in order to finesse the complexities.
Medicare was supposed to have the exact same coverage for services throughout the US but during
the early 2000’s some of the fiscal intermediaries had slightly different policies or effective dates
for service coverage. E.g. different regions (primarily) of the country had different start dates for
coverage of SLNB depending on which fiscal intermediary (FI) processed a hospital’s claims. An
additional issue is that, according to a Medicare data training workshop provided by RESDAC,
a person always has the same FI processing their claims as when they first signed up. Thus,
individuals that moved during the time period where there were differences in FI policies may
have had the policies imposed based upon their previous residence’s FI.
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Concluding this section is a description of the SEER-Medicare data methodology.
SEER-Medicare data Methodology
SEER-Medicare methodology is as follows. From the SEER website, “Geographic areas were
selected for inclusion in the SEER Program based on their ability to operate and maintain a high
quality population-based cancer reporting system and for their epidemiologically significant pop-
ulation subgroups. The population covered by SEER is comparable to the general US population
with regard to measures of poverty and education. The SEER population tends to be somewhat
more urban and has a higher proportion of foreign-born persons than the general US population.”
Thus, it is not a probability sample and all generalizations to populations outside of the SEER re-
gions must be model based. This data is then linked to Medicare eligibility data and a 94% linkage
rate has been found for cases where the first cancer occurred at an age of 65 or greater. Cases
where there is a successful link are kept.
The data file creation process starts with SEER data being transformed from the format of one
record per incidence of primary cancer to a person level format. The data for the first ten cancers
is retained, i.e. it is changed from tall to wide structure with truncating any incidences of cancer
after the first ten. Variables are created for each of the (up to) ten cancers including all the different
coding systems over time. This leads to many empty data elements and requires knowledge of
which set of variables are to be used for any given incidence of cancer. This is determined by
cancer number, date of diagnosis, and for a few variables cancer type.
This information is combined with demographic and eligibility information from the Medicare
program to create the Patient Entitlement and Diagnosis Summary File (PEDSF) file. The name is
a little misleading as it includes all of the (selected by NCI) SEER data, not just the diagnosis infor-
mation. It also includes (de-identified and ‘fuzzed’) census tract and zip code level demographic
(census) information.
In this next section Rogers theory of the diffusion of innovation is reviewed. It is a theory that
has informed and framed much of the work done in modeling the use of SLNB.
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1.1.4 Rogers Theory of the Diffusion of Innovation
Before looking at individual studies on the use of SLNB, it is useful to consider Rogers’ (1962)
theory on the diffusion of innovation. It explicitly is part of the conceptual basis of at least two
papers on the use of SLNB (9; 44) and will be used in the development of the model in this
work. He proposed that the uptake by a population of an innovation, be it a product, an idea, or
a procedure, follows a consistent pattern. This pattern can be described by a S-shaped curve on a
graph, with the proportion of a population that has adopted the innovation on the y-axis and time
on the x-axis. It has aspects of a cumulative distribution function and is similar in shape to the
logistic function, with the exception that it starts at zero and can eventually reach 100%. Thus the
model should permit examining whether it is the case with the diffusion of SLNB.
The taxonomy for Rogers’ five categories of adopter types is Innovators, Opinion Leaders,
Early Majority, Late Majority, and Laggards. He suggests that the proportion of a population that
falls into each category is, respectively, 2.5%, 13.5%, 34%, 34%, and 16% and it’s around the point
when 16% of the population has adopted the innovation that the function begins its steepest slope.
I hypothesize that at the hospital level that one will be able to identify these different adopter types
and thus the model should permit testing this as well. In the case of assessing the rate of use of
a procedure over time, one way to identify the different categories is by graphical examination of
individual hospitals’ rate of use of over time. Numerically, a formula could be devised to categorize
hospitals based upon their subject specific intercept terms and the subject specific polynomial if
the effect of time is included in a model.
A limitation of Rogers model is that it only speaks to the time period when adoption is occur-
ring and thus is a non-decreasing function over time. It also is limited to the choice of adopt or
not adopt, so differential adoption isn’t explicitly addressed. One could however easily imagine
separate curves for different situations i.e. the curve is conditional upon some set of factors. For
modeling the use of a procedure over a longer timespan it would be useful to consider the possibil-
ity of decreasing use, particularly for subpopulations. Possible reasons for decreasing use among a
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(sub)population are, the procedure is found to have issues, it is supplanted by a newer technology,
there is a substantial increase in cost to payer relative to alternatives (or benefit), and a change in
incentives to the decision maker that reward different choices. Thus we need to extend Rogers’
theory to model the lifecycle of a procedure where there is a decreasing component at some point.
A good model will permit testing for these possibilities. In the case of a model that uses a global
polynomial to measure the effect of time, it essentially requires the use of a cubic term.
In section 1.2, seven papers that examined the use of SLNB in early stage breast cancer are
reviewed, starting with their methodologies, variables, and results in subsection 1.2.1 and then
with a greater focus on the statistical models employed in subsection 1.2.2.
1.2 Previous Research in the use of SLNB in Early Stage Breast Cancer Treatment
With Rogers’ theory in mind let’s examine some of the work to date on the use of SLNB in
breast cancer treatment.
1.2.1 Methodology, Variables and Results
Maggard et al. (2005) (35) used SEER data from 12 regions from 1998 to 2000, treating patient
as the unit of analysis, and performed multivariable logistic regression to identify predictors of the
use of SLNB during that time frame. Included were those cases that had an AJCC stage of I or II.
Those cases with “Histologies corresponding to squamous cell, spindle cell, carcinoid, sarcoma,
Paget’s disease, and in situ tumors were excluded from the analysis.”(35) They must have received
definitive surgery, Lumpectomy or Mastectomy, and received SLNB, ALND, or both.
Variables included in the model were all categorical (reference levels are underlined) and in-
cluded; SEER Registry, Tumor grade, Tumor stage (I, II), Age at diagnosis (<40, 40-49, 50-59,
60-69, 70-79, and 80+), Race/ethnicity (White, Black, Hispanic, Asian, and Other), Marital status
(Not married vs. Married), Year of diagnosis (1998, 1999, 2000), and Surgery type (Lumpectomy
vs. Mastectomy). While stating that they controlled for registry and tumor grade they did not
give any information about how these variables were handled in the model. They found that older
women and minority groups, as well as those receiving mastectomies were less likely to have a
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SLNB performed then their respective reference groups.
Chen et al. (2008) (11) used National Cancer Database data from 1998 to 2005, treating patient
as the unit of analysis, and performed several multivariable logistic regressions to examine the ef-
fect of patient, clinical, facility, and neighborhood characteristics, as well as year, on the receipt of
SLNB. Inclusion criteria were; TNM staging of T1N0M0 or T2N0M0, received definitive surgery,
received nodal staging, and no missing demographic data. They found all of the variables included
in their models to be highly statistically significant with the exception of a few levels (mostly the
‘missing’ level) of a small number of variables. No attempt was made to do multi-level modeling
despite the clearly multi-level nature of the data.
It should be noted that Urbach and Austin’s (2005) (53) paper ‘Conventional models overesti-
mate the statistical significance of volume-outcome associations, compared with multilevel mod-
els’, in the Journal of Clinical Epidemiology, points out just that, along with providing an example
analysis using hospital procedure volume to predict an outcome. This of course would generalize
to any higher level covariate in a multi-level structure, but is particularly of note since several of
the SLNB papers use hospital procedure volume as a predictor variable including Chen et al.
Rescigno, Zampell, and Axelrod (2009) (45) used SEER data from 14 regions from 1998 to
2004, treating patient as the unit of analysis, and performed multivariable logistic regression to
examine factors involved in the nodal staging procedures used. Inclusion criteria were; T1 to T3,
N0 and N1, and M0 based on TNM staging, received definitive surgery, and status of nodal staging
known. Variables included in the model were at the disease, patient, and neighborhood levels but
no hospital level information was included. They found both appropriate and inappropriate use
of SLNB and ALND, with significant effects of disease factors, age, Hispanic (but not African
American) ethnicity/race, and neighborhood level demographics.
Carpenter et al. (2011) (9) used SEER-Medicare data from seven regions from 2000 to 2002
and employed a three level multilevel model where patient was nested within hospital, which was
nested in SEER region, to examine the factors involved in the diffusion of the use of SLNB during
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this time frame. The model was implented by use of a Generalized Linear Mixed Model with
random intercept terms for hospital nested within SEER region and SEER region. Inclusion criteria
were; 66 or older at the date of first diagnosis of primary breast cancer, 12 monthsMedicare parts A
and B eligibility prior to diagnosis, 24 months Medicare parts A and B eligibility post diagnosis (or
until death), no HMO coverage during the study period, were not identified via autopsy nor death
certificate, received definitive surgery, and received nodal staging. Variables included in the model
were at the disease, patient, neighborhood, hospital, and regional levels. They found that hospital
level variables, other than year, had the largest effect, African Americans and older patients were
much less likely to receive SLNB, and many variables previously reported to be significant were
not found to be statistically significant.
Reeder-Hayes et al. (2011) (44) used the same data as Carpenter et al. but performed multivari-
able logistic regression with GEE estimation of within hospital correlations. Variables included in
the model were similar as Carpenter et al. but included a variable for receipt of Medicaid, which
was found to have a rather large (OR 0.61, C.I. 0.47,0.78) and significant effect.
Meyer et al. (2013) (38) used SEER-Medicare data from 2000 to 2005 but it is unclear what
their model actually was. In the abstract they say they used a generalized linear model with gen-
eralized estimating equations while in the text they say they used SAS’s PROC GLIMMIX which
‘uses random effects and takes into account the clustering of patients within physicians and physi-
cians within hospitals.’ They also indicate that they used Maximum Likelihood with the Laplace
method for numeric integration. Given the lack of a clearly stated model we are unable to assess it
further.
Arrington et al. (2013) (3) used SEER data from 1998 to 2008 looking across all ages with a
focus on urban vs. rural populations. They used multivariate logistic analysis but did not control
for the hierarchical nature of the data.
Next we focus more in depth on the statistical models that the five papers with known models
used for their analyses.
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1.2.2 Statistical models
In this section we will look at the statistical models used in each of the papers, including
the model assumptions. The three model types used are all variants of logistic regression. They
are binomial logistic regression, a marginal model with generalized estimating equation (GEE)
estimates of parameters including within cluster correlation, and a generalized linear mixed model
(GLMM). To begin we consider the papers that used binomial logistic regression.
Binomial logistic regression - A type of generalized linear model
Four of the papers considered used binomial logistic regression for modeling the receipt of
SLNB. There is a substantial body of literature on logistic regression but a standard reference is
McCullagh and Nelder (1989) (37), whose notation and terminology is used in this section. For
describing logistic regression McCullagh and Nelder use the framework of generalized linear mod-
els (GLM) originally developed by Nelder and Wedderburn (1972) (40). The main components of
a GLM include the error distribution, a link function, and the systematic component. The vari-
ance function and the dispersion parameter stem from the choice of main components. Thus for
the case, such as in the first three papers, where there are only categorical explanatory variables,
binomial logistic regression can be described as follows:
Model description
LetN be the total number of patients observed in a study. x is a vector of length p whose elements
consist of categorical explanatory variables. A covariate class, such as described in McCullagh
and Nelder (1989) (37), is a distinct combination of covariate levels for the explanatory variables.
There are n covariate classes and i is the index for the covariate classes such that i = 1 to n.
Thus, a covariate class is all observations that have the covariate vector (xi1, xi2, . . . , xip). mi is
the number of observations in the ith covariate class.
Now, letY be the response vector of length n consisting of counts of receipt of SLNB for each
covariate class. pi is a vector of length n consisting of the probabilities of SLNB for each covariate
class. η is a vector of length n consisting of the log odds of SLNB for each covariate class. β is
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the parameter value vector of length p. X is the design matrix of size p×n. m is a vector of length
n consisting of the covariate class counts.
Then using the GLM framework and the case of binomial logistic regression with categorical
explanatory variables; we have error distributions that are binomial and independent, use of the
logit for the link function, and a systematic component that is linear on the logit scale. These main
components of the GLM as well as the corresponding variance function and dispersion parameter,
φ can be written for each covariate class as follows:
Error distribution Yi ∼ Bin(mi, pii), where Yj ⊥ Yk and j 6= k





Systematic component ηi = x
T
i β





The primary model assumption is that conditional upon the explanatory variables the binary
outcomes are generated by a bernoulli process with each event independent and identically dis-
tributed. Another important assumption is that the model is correctly specified and all necessary
independent variables are included in the model. Parameters can be estimated with maximum like-
lihood estimation although the EM algorithm is needed if there are missing values for any of the
explanatory variables.
Parameter Estimation
Parameter estimation can be accomplished via either the Iteratively Reweighted Least Squares
Algorithm, also known as Fisher Scoring, or by use of the Newton-Raphson Algorithm. Proc
Logistic in SAS defaults to Fisher Scoring and it is described in the documentation as well as a
more complete description in McCullagh and Nelder (1989) (37). Following is a description of the
process using Fisher Scoring drawing heavily on McCullagh and Nelder (1989) section 4.4.
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in matrix notation becomes:
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WhereW (in reduced form) is a diagonal weight matrix:
W = diag {mipii (1− pii)}
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Let Z, the adjusted dependent variable, have components:





McCullagh and Nelder’s 4.16 is the equation that maximum likelihood estimates satisfy:
XTWXβˆ = XTWZ
Parameter estimates can be obtained by starting with a value for βˆ, say βˆ(0), based upon initial
estimates for pˆi(0) using the data (with an appropriate adjustment for the cases where pˆi
(0)
i = 0 and
pˆi
(0)
i = 1) and then solved iteratively using least-square methods.







With values on the right based upon the estimates from the previous iteration. The process is
continued until convergence is obtained.
In the next section we look a paper that used a marginal model in an attempt to control for the
within cluster correlation.
Logistic regression - Marginal model
Reeder-Hayes et al. (44) used a marginal (population averaged) model and GEE based esti-
mates of the parameters with an unstructured correlation matrix. This model, unlike the previous,
takes into account the fact that observations from the same hospital are likely to be correlated by
treating the hospital as a cluster and modeling the within cluster correlation. It is called a marginal
model to emphasize the fact that only the explanatory variables are used in generating the explana-
tory parameter estimates. The specifics of the model are as follows:
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Model description
Let N be the total number of patients observed. There are n hospitals (clusters) and i is the index
for the hospitals so that i = 1 to n. j indexes the patients within a hospital and there are mi
patients in the ith hospital, so j = 1 to mi. The response vector Yi = (Yi1, . . . , Yimi)
T consists of
zeros and ones that indicate each patients (non)receipt of SLNB. The components of the model are
as follows:
Error distribution Yij ∼ Bern(piij)





Systematic component ηij = x
T
ijβ
Variance function piij(1−piij) Correlation structure Corr (Yij, Yik) = αjk
Note that in this type of model the expected value and the variance of Yij are modeled sep-
arately. Also note that since only the first two moments are given a likelihood function can not
be specified. This leads to the use of quasi-likelihood estimates for the parameters. The model
assumptions include that any missing outcome data is missing completely at random (MCAR)
(46; 31).
Following is a description of the estimation process, it is based heavily on course notes from Pro-
fessor Herring’s longitudinal data analysis class which for this topic are based on Liang and Zeger
(1986) (31).
Parameter Estimation




i where Ai is a diagonal matrix
with the values of v (µij) on the diagonal and R (α) is the working correlation matrix indexed by
α.










A two stage iterative procedure is then used. 1. With the current estimates of α and φ we obtain






The last model considered is a three level random effects model, found in Carpenter et al. (9).
Logistic regression - Three level random effects model
The statistical model employed in Carpenter et al. (9) uses a generalized linear mixed model
with a logit link function. It is a three level random effects model with random intercept terms for
hospital nested within SEER region at the second level and SEER region at the third level. There
are fixed effect covariates at the person (first) level as well as at the hospital (second) level.
It can be formulated as follows:
Model description
Let N be the total number of patients observed. There are m third level units, SEER regions,
which are indexed by k such that k = 1 to m. There are nk second level units, hospitals, in each
third level unit which are indexed by jk. Let ljk be the count of first level units, patients, in each
hospital, indexed by ijk. Thus, the jth hospital in the kth SEER region has ljk patients. Let Y be
the response vector of length N consisting of zeros and ones indicating each patients (non)receipt
of SLNB. pi is a vector of length N consisting of the expected value of Y , that is the probability
of SLNB, for each patient. η is a vector of length N consisting of the log odds of SLNB for
each patient. x
(1)
ijk is a vector of length p whose elements consist of first (patient) level explanatory
variables. x
(2)
jk is a vector of length q whose elements consist of second (hospital) level explanatory
variables. β(1) and β(2) are the corresponding fixed effect parameter value vectors of length p and
q respectively. b(2) and b(3), are multivariate normal random variables with means of zero and
b ∼MVN (0,G), whereG is the covariance matrix.
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The three levels of the systematic component for each patient are:










Third level model β0k = β0 + b
(3)
k
Thus, β0 is the fixed effect that represents the mean of the logit across all SEER regions, β0k is
the mean value for the kth SEER region, and β0jk is the mean value for the j
th hospital in the kth
SEER region.
Parameters were estimated using maximum likelihood but required the use of quadrature in
order to generate the estimates. This model assumes that any missing outcome variable data are
missing at random (MAR) (46; 28; 49).
The following description of the estimation procedure draws heavily on the SAS documentation
(47) for the procedure used to fit the models, Proc GLIMMIX (see chapter 38), as well as Professor
Herrings 767 course notes.
Parameter Estimation
The joint probability density function, in general, is given by:
f (Yi|Xi,bi) f (bi)




f (Yi|Xi,bi) f (bi) dbi
A two step procedure is used to get the maximum likelihood estimates, first obtain estimates
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for β andG based on the marginal likelihood, using adaptive quadrature numerical integration for













where p (x) is a probability density function, f (x) is some function to be integrated against
it, Q is the number of quadrature points, r is its index, and wr are the quadrature weights. In
our case f (x) is the conditional distribution given the random effects, and p (x) is the random
effects distribution. When the number of quadrature points is not specified ahead of time then
Proc GLIMMIX determines the number of quadrature points by evaluating the log likelihood at an
increasing number of points until a tolerance is met. Additionally, and separately, ‘the procedure
centers and scales the quadrature points by using the empirical bayes estimates (EBEs) of the
random effects and the Hessian matrix from the EBE suboptimization.’ The manual goes on to
state that this process improves the likelihood approximation ‘by placing the abscissas according
to the density function of the random effects.’
1.2.3 Limitations of Current Work
Looking at Carpenter et al. (9), being the work that most closely modeled the structure inher-
ent in SEER-Medicare data of the papers considered, we find several limitations that impair the
interpretability of the results.
Failure to account for repeated measures
One major limitation is the failure to take into account the repeated measures nature of the data,
this is compounded by the collapsing to diagnosis year from diagnosis month. The data provided
by the SEER-Medicare program provides the month of diagnosis rather than the exact date to help
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ensure anonymity of the patients. This study, like the others, however collapses the data to year
of diagnosis which both obscures within year trends and leads to having unidentified clusters, the
hospital and diagnosis month combination, within each diagnosis year. It’s been shown that failing
to include all levels in a binary response multilevel model leads to biased estimates (51). Using
a Laird and Ware repeated measures type model (28) treating the hospitals, nested within region,
as the units and maintaining the uniqueness of the diagnosis month, would have permitted more
accurate parameter and standard error estimates and provided more information about the shape of
the outcome trajectory.
Failure to account for covariates measured with error
Despite the potential for measurement error in the covariates, as is customary in many fields, the
covariates are treated as if they were perfect measurements of the construct of interest in all of the
papers considered. It has been shown that treating stochastic variables in a GLMM as if they were
non stochastic can lead to bias in parameter estimates and decreased precision of the estimates (57).
Models for GLMMs with measurement error in the covariates have been described as generalized
linear mixedmeasurement error models (GLMMeM) (58) and over the past 15 years or so, a variety
of approaches have been developed for working with this class of models. Several methods have
lately been proposed for addressing this issue primarily via the use of instrumental variables and
alternatives to maximum likelihood for parameter estimation (30; 42). Other approaches include
regression calibration, simulation extrapolation, likelihood based methods, and Monte Carlo EM
(MCEM) algorithm estimation of the MLE. (64; 7).
In regression calibration the true value of the covariate measured with error is predicted by
use of a regression model based upon the other available covariates. The predicted values are
then used in place of the original measured with error values in the model of interest without any
further adjustments. There are however issues with regression calibration for GLMMeMs with
binary outcomes as pointed out in Carrol et al. (2006) (10). While in general substituting the
predicted values would correctly specify the fixed effects structure in a GLMM (given that it was
orthogonal to the random effects structure) it doesn’t correctly specify the random effects structure.
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Given that in the binary outcome case they are not orthogonal then both the random effects and the
fixed effects estimates will be biased (58).
Simulation extrapolation is most suited for measurement errors that are additive (10) and gives
an approximate but inconsistent estimator (30). While the numerical integration estimates of the
(intractable) log likelihood suffer from high dimensionality of the random effects (64). TheMCEM
approach can have computational challenges such as non-convergence due to the random effects
(64). Thus Li and Wang’s (2012) (30) approach combining instrumental variables with a method
of moment estimator (MME) using a simulation based approach in the cases (such as a GLMMeM
with a binary outcome) where the moments are intractable may be a useful tool. Their simulation
based approach also has the benefit of not requiring normally distributed random effects (29).
Limited Model Checking
Another limitation is that limited model checking was performed. While likelihood ratio tests
indicated that the fixed and random effect terms in the final model provided a better fit than the
models without them, no checking of model assumptions, particularly the normality of the random
effects, was attempted. It is known that the maximum likelihood parameter estimates for binary
outcome type Generalized Linear Mixed Models are sensitive to departures from normality for the
random effects (21; 18; 34; 33). Methods have been proposed for testing for model misspecification
but were not used (1). Perhaps it would be better to assume an alternate distribution or to use a
nonparametric estimate of the random effect (27; 2; 29). Tests for normality of the random effects
have been proposed (50; 18) and could have been used to test the need for non-normal random
effects.
Methodological Limitations
Methodological limitations primarily were a function of the exclusion criteria for the study,
they included: only examining a fairly short time span even though more data was available, using
data from a limited number of SEER regions (seven), excluding those patients that did not receive
any nodal staging, and excluding those cases whose staging information possibly did not meet
the criteria for use of SLNB. While there were reasons for all of these decisions there also are
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approaches, either statistical or methodological, that would permit use of a much larger and richer
analytical data set that would provide both more power and greater insight into when SLNB was
performed.
In the next section we consider estimators of the variance parameters of the random effects in
Generalized Linear Mixed Models and some methods to compare thier relative efficiency.
1.3 Random Effect Parameter Estimation in Generalized Linear Mixed Models
The two primary methods for estimating the variance parameters of the random effects in Gen-
eralized Linear Mixed Models are Maximum Likelihood (ML) (with numeric integration) and
Pseudo-likelihood (PL) (also called penalized quasi-likelihood). ML is the gold standard, partic-
ularly for binary outcomes, but is computationally intensive. The ML using quadrature algorithm
that is implemented in SAS Institute’s Proc Glimmix has been described in section 1.2.2.
1.3.1 GLMM specification
In this section we will use the following specification of the GLMM.Note that g−1 is the inverse
link function and in this section Z is the design matrix for the random effects. Other terms are as
defined previously in section 1.2.2.





V ar(Y |b) comes from the exponential family
1.3.2 Pseudo-likelihood (PL)
The use of Pseudo-likelihood for estimation of variance parameters in a GLMM was proposed
in two separate papers in 1993 (5; 63). Both approaches make use of the generalized mixed model
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Where y∗, the ‘pseudo-data’, is alternately used to estimate β and b and is estimated using
their estimates from the previous iteration. Given its relative ease of computation it was the original
method used in Proc Glimmix and remains the default method.
In the next section bias in these estimators is discussed.
1.3.3 Bias in Estimates
It has been shown that for GLMMs with binary outcomes that PL based random effect variance
estimators are biased with the magnitude of the bias inversely related to cluster size (6; 32; 43).
ML based estimates have been found to have less/little bias in this case with quadrature based
approximations performing the best and Laplace based approximations somewhat less so (43).
In the next section one potential way of addressing parameter estimator bias is covered, the
jackknife procedure.
1.3.4 Jackknife process
The Quenouille-Tukey jackknife is a procedure for nonparametrically estimating a function
(statistic) of some unspecified distribution from the data at hand that should have less bias than
some simpler estimator and is a special case of bootstrapping (16). Simply put, the jackknife
estimator is the average of all possible instantiations of some estimator where a single data point
is left out of its calculation.
Parameter Estimation
The following specifies the jackknife estimator, θˆ(.) for some estimator θˆ.








Bias Estimation and correction
Bias estimation can be done by Quenouille’s estimate of bias
B̂IAS = (n− 1)(θˆ − θˆ(.))
and the bias corrected estimator is simply
θ˜ = θˆ − B̂IAS
The next section covers three types of relative efficiency for multivariate estimators such as the
estimators of covariance matrices.
1.3.5 Comparing estimators via D-, A-, and E-efficiency
This section heavily draws on section 8.6 of Jureckova, Sen, and Picek (2011) (23) where
they discuss multivariate efficiency. In all three types of relative efficiency we will consider the
reference is the ML estimator and it is the Fisher information from that which is compared to the
asymptotic covariance matrix of the estimated random effects variance terms from the estimator
which is under consideration. Essentially each type of efficiency is a different statistic of the
eigenvalues of the product of asymptotic covariance matrix and the MLE Fisher’s information.
The specifics follow.
Let Tn be the estimator of interest of parameter θ, in our case the covariance matrix of the
random effects, and let υT be the dispersion matrix of
√
n(Tn − θ). Let I(θ) be the Fisher
information matrix andD0 is the diagonal matrix of the p eigenvalues of υTI(θ).
Then we have:
D-efficiency
is the pth root of the determinant of (D0)−1
A-efficiency
is the mean of the eigenvalues of (D0)−1
23
E-efficiency
is the largest eigenvalue of (D0)−1
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2 CHARACTERIZING INNOVATION ADOPTION
2.1 Introduction
Quality of care in the treatment of cancer is an important issue and awareness has been height-
ened ever since the Institute of Medicine released its recommendations in Ensuring Quality Can-
cer Care (39). One of the IOM’s recommendations of primary importance to this work is to
“Measure and monitor the quality of care using a core set of quality measures.” Other recommen-
dations included; “Services for the un- and underinsured should be enhanced to ensure entry to,
and equitable treatment with, the cancer care system”, “Studies are needed to find out why specific
segments of the population ... do not receive appropriate cancer care”, and “Cancer care quality
measures should be used to hold providers ... accountable for demonstrating that they provide and
improve quality of care.” While the first and last call explicitly for a set of metrics, the other two
implicitly require metrics in order to be achieved. The focus of this work is to generate the basis
for a metric that can be used to measure, and ultimately improve, quality of medical care for all
patients.
One indication that quality care is being provided is the use of new evidence based procedures.
However, to date, there is no metric that captures the pattern of institutional adoption of a new
evidence based procedure. We propose that Innovation Adoption Trajectories could be used as the
basis for such a metric. The example we apply this approach to is the case of the adoption of Sen-
tinel Lymph Node Biopsy (SLNB) for pathologic lymphatic staging of early stage breast cancer
in the Medicare population. The statistical model used to generate these trajectories is a Logis-
tic Normal Generalized Linear Mixed Model. In the next three sections we define and describe
the theoretical basis for Innovation Adoption Trajectories, provide background information about
Sentinel Lymph Node Biopsy, and give a brief description of how the model is used to generate
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trajectories of the probability of use of SLNB.
We begin with a description of Innovation Adoption Trajectories.
2.1.1 Innovation Adoption Trajectories
We define innovation adoption trajectories as the model based estimates (or predicted values)
of the probability of use of a clinical trial proven procedure over the period of adoption of the
novel procedure by the medical community. It is proposed that these trajectories, derived from
institutional claims and registry data, can be a useful tool for understanding promoters and barriers
to evidence based medical practice. Characterization of these trajectories is motivated by Rogers’
(1962) theory of adoption of innovation.
Rogers proposed that the uptake by a population of an innovation, be it a product, an idea, or
a procedure, follows a consistent pattern. This pattern can be described by a S-shaped curve on a
graph, with the proportion of a population that has adopted the innovation on the y-axis and time
on the x-axis (Figure 2.1 - red dashed line). It is similar to the cumulative density function (CDF)
of the normal distribution, with the exception that it starts at zero and can eventually reach 100%.
He also proposed that there are five ‘adopter types’ in a population.
His taxonomy for these adopter types is Innovators, Early Adopters, Early Majority, Late Ma-
jority, and Laggards. He suggests that the proportion of a population that falls into each category
is, respectively, 2.5%, 13.5%, 34%, 34%, and 16%, the distribution of which resembles the proba-
bility density function of the normal distribution (Figure 2.1 - blue solid line).
Note that in Rogers’ theory it is assumed that an individual either uses or doesn’t use an in-
novation. Our innovation adoption trajectories assume that an individual (e.g., institution) has
multiple opportunities to make use of the innovation and does so with some probability that can
vary over time. It is assumed prototypically that these trajectories are monotonically increasing
functions over the time period that the medical community is adopting the innovation and have an







































































Figure 2.1: Distributions of Rogers’ adopter types
trajectories corresponding to the different adopter types are shown in Figure 2.2. These hypothet-
ical trajectories were generated using the CDFs of five Weibull distributions. The parameters for
these distributions were selected to approximate a 0.8 probability of use of the innovation at the
theoretical time point that an adopter type starts adopting an innovation and are simply meant to
be illustrative. To the best of our knowledge this is a novel extension of Rogers’ theory.
It is hypothesized that the trajectory of the medical procedure’s use is determined by the culture
of the institution as well as patient characteristics including morbidity. Institutional affiliations are
proposed as a proxy for institutional culture.
Next we describe SLNB and give some background about it’s adoption and describe why it is
a preferred staging procedure, in some cases, relative to the previous standard. Previous research
on it’s adoption is also presented.
2.1.2 Adoption of Sentinel Lymph Node Biopsy
The example used in this work is the case of the adoption of sentinel lymph node biopsy










































Figure 2.2: Hypothetical innovation adoption trajectories by adopter type.
of 1999 to 2007 when it was starting to be adopted by the medical community. Originally called
sentinel lymphadenectomy (20), it was being used in place of Axillary Lymph Node Dissection
(ALND) in some cases when appropriate (20; 8; 15; 19), although seemingly with disparities for
at risk groups (22; 35; 11; 45; 9; 44; 38).
Lymph Node Staging Procedures
Axillary Lymph Node Dissection (ALND)
ALND involves the removal of all level one and two ipsilateral axillary lymph nodes. It is an
extensive procedure and associated morbidities include, lymphedema, nerve paresthesias, axillary
seromas, and infections. Its primary purpose is to provide pathological nodal staging information.
It also serves the function of removing any metastatic tissue that is involved with the axillary lymph
nodes.
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Sentinel Lymph Node Biopsy (SLNB)
SLNB is a less invasive procedure than ALND, where a few lymph nodes are removed, typi-
cally 1 to 3, and intraoperatively assessed for metastatic involvement (8; 24). A standard version
of the procedure during the time frame of this study started with injecting a blue dye and a radioac-
tive tracer near the site of the tumor (36). After some time has passed both visual inspection and
a Geiger counter are used to determine which lymph node(s) the lymph near the tumor drains to.
These are excised and assessed for metastatic involvement. If it is determined that there is involve-
ment then the next node in the lymph chain is excised and examined. Using this information it can
then be determined whether to perform a completion ALND.
SLNB as Standard of Care for Early Stage Breast Cancer Treatment
Up through the late 1990’s the standard practice had been to perform ALND for pathologic
lymph node staging in cases of early stage BC. With the advent of SLNB in the mid 1990’s and
a growing body of evidence that it was equivalent to ALND in outcomes for pathologic node
negative cases it became the standard of care (62; 13; 52; 14; 41; 54; 55; 61; 56). Medicare started
reimbursing its use in 1999 while it was still in clinical trials since early evidence suggested it was
a preferred treatment option in many cases. With the conclusion of the clinical trials SLNB became
the documented standard of care for lymphatic staging of early stage breast cancer (26).
Previous Research
Factors that have been associated with the rate of SLNB’s use over time include disease, patient,
neighborhood, physician, institutional, and regional characteristics (22; 35; 11; 45; 9; 44; 38; 3).
However, to date, the literature on this topic does not take into account both the multilevel and
repeated measures over time aspects that are inherent in this data. Prior research on factors
influencing the use of SLNB in BC treatment primarily used multivariable logistic regression
(22; 35; 11; 45; 3). Two studies used intercept only random effects models (9; 38) to control
for the multilevel nature of the data. One study used logistic regression with GEE based estimates
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of the within hospital correlations (44). These last three studies essentially assumed that the cor-
relations between any two patients within a given hospital were the same regardless the amount
of time between their diagnoses. All of these works treated time (diagnosis year) as an unordered
categorical variable.
The next section briefly describes the statistical model used and how trajectories are generated
from it.
2.1.3 Use of Generalized Linear Mixed Model
The method we used to generate innovation adoption trajectories is to model the receipt of the
novel procedure (0,1) at the patient level by applying a generalized linear mixed model (GLMM
- logistic normal). This model is parameterized to capture the multilevel (patient, institution, and
region) and longitudinal nature of the data. This type of model has been extensively described
(28; 49; 17) as well as best practices for fitting (12; 1). We then make use of the estimated values
over time, based upon the fixed effects, to generate regional trajectories. Generation of institutional
trajectories is accomplished by calculating the predicted values over time for a given institution by
combining the relevant region and hospital level fixed effects and the best linear unbiased predictors
(BLUPs) of the random effects for that institution.
2.2 Methods
2.2.1 Data
We make use of the Surveillance, Epidemiology, and End Results (SEER)-Medicare database
which has both cancer registry and procedure claims data, as well as some patient demographics
and institutional data (59; 4; 25; 48). It is derived from 14 cancer registries covering 17 geographic
regions across the US. Individual cases are linked to the corresponding Medicare claims and el-
igibility information. For those cases where the first primary cancer occurred at an age of 65 or
greater there is a success rate of 94 percent in linking to Medicare data. It has been described
extensively elsewhere, particularly in a supplement to Medical Care in 2002 (59; 4; 25; 48). What
follows in a basic description of each of the components.
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We start with the cancer registry data and how it’s collected.
SEER Cancer Registry Program:
The National Cancer Institute’s Surveillance Research Program contracts with state health pro-
grams and universities to operate incident cancer registries in geographic regions around the United
States of America. Currently the registries cover about 28% of the US population. The 17 reg-
istries are each headed by a different investigator and each registry works differently. They do
however use a standardized reporting system for data transmission to NCI. When data is received
by NCI it is stored in a format of one record per incident cancer diagnosis. It should be noted
that the program is for the most part facility based and thus information for services provided in a
physician’s office might be missing or incomplete. It should also be noted that for many variables
there is a hierarchical structure, that is, some values supersede other values even though both are
true (e.g., the maximum value is reported). The types of data included are: diagnostic, staging,
treatment, and limited demographics.
Registry data can come from a variety of sources, but a case is first identified via a report from:
a service provider where a cancer diagnosis was made, an autopsy report, or from a death certifi-
cate submitted to the cancer registry for the geographical region where the entity is located. In
SEER-Medicare research it is a standard practice to exclude those cases that were only identified
via autopsy or death certificate. Thus the reporting sources include at least one of: a Hospital Inpa-
tient/Outpatient or Clinic, a Laboratory (Hospital or Private), a Physician’s Office/Private Medical
Practitioner, or a Nursing/Convalescent Home/Hospice.
There are a variety of missing data issues for SEER data. Registries don’t capture 100% of
all incident cases, although the expectation is at least 98%. Missing data is more likely to have
come from patients who were primarily treated at physician’s offices (rather than at a hospital
or clinic). Pathological staging data ‘overwrites’ clinical staging data and if is unknown if this
has occurred for breast cancer (prostate cancer has separate clinical staging variables). Changes
in coding systems over time have led to some staging and treatment information being collected
during some time frames but not others (or defined somewhat differently). Race data categories
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depend on time period, SEER race data however is considered better than Medicare race data. Six
months of 2005 data for Louisiana are somewhat sparse due to severe storms and an indicator
variable flags this time period. There were four new SEER registries in 2000 and there is no prior
data for them.
Finally it should be noted that SEER data is not a probability sample and all generalizations
to populations outside of the SEER regions must be model based. From the SEER website, “Geo-
graphic areas were selected for inclusion in the SEER Program based on their ability to operate and
maintain a high quality population-based cancer reporting system and for their epidemiologically
significant population subgroups. The population covered by SEER is comparable to the general
US population with regard to measures of poverty and education. The SEER population tends to
be somewhat more urban and has a higher proportion of foreign-born persons than the general US
population.”
Next we consider the Medicare data that is provided by NCI in their release of SEER-Medicare
data.
Medicare data as Provided by the SEER-Medicare Program:
Medicare data used in this study consists of eligibility, inpatient stay, outpatient service, physi-
cian service, and durable medical equipment (which includes some cancer medications) informa-
tion. Medicare eligible individuals include qualifying individuals age 65 or greater, those with end
stage renal disease, and certain people with disabilities. Note that this is administrative (billing)
claims data for services that are paid for based on Medicare policy in effect at the time of ser-
vice. This has implications for completeness, particularly for procedures not covered at the time
of service.
Medicare data also has its share of missing data issues. Physicians tend to be erratic in billing
for services they know Medicare won’t pay for, so for uncovered services there will be ‘missing’
claims data. Similarly some services are ‘bundled’ with others and only the code for the more
extensive procedure is provided. One needs to be familiar with Medicare policy during time period
of interest and during some years the location of interest in order to finesse the complexities.
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Medicare was supposed to have the exact same coverage for services throughout the US but
during the early 2000’s some of the fiscal intermediaries (FI) had slightly different policies or ef-
fective dates for service coverage. E.g. different regions (primarily) of the country had different
start dates for coverage of SLNB depending on which FI processed a hospital’s claims. An ad-
ditional issue is that a person always has the same FI processing their claims as when they first
signed up. Thus, individuals that moved during the time period where there were differences in FI
policies may have had the policies imposed based upon their previous residence’s FI.
An overview of SEER-Medicare data methodology follows.
SEER-Medicare data Methodology:
SEER-Medicare methodology is as follows. Selected SEER registry data elements (those ele-
ments with known poor reliability are excluded) from each incident cancer diagnosis, up to the first
ten, are put into a format of one record per person. This data is then linked to Medicare eligibility
data and a 94% linkage rate has been found for cases where the first cancer occurred at an age of
65 or greater. Cases where there is a successful link are kept. It is unknown whether there is any
selection bias in the linkage process but assumed not.
This information is combined with demographic and eligibility information from the Medicare
program to create the Patient Entitlement and Diagnosis Summary File (PEDSF) file. The name
is a little misleading as it includes all of the (selected by NCI) SEER data, not just the diagnosis
information. It also includes (de-identified and ‘fuzzed’) census tract and zip code level demo-
graphic (census) information. Census data sometimes is missing, and the usual strategy is to use
zip code based data in this case. There are however, still a (very small) number of missing values
after this strategy is employed.
Next is the inclusion criteria for this study.
Inclusion Criteria
The main inclusion criteria for this study are that the Medicare recipient is female with her first
or only incident primary breast cancer occurring during the years of 1999 to 2007. A valid diagno-
sis month must be present and the reporting source must not be autopsy nor death certificate. This
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cancer must have occurred at age of 66 or later and the basis for Medicare coverage must not be
End Stage Renal Disease (ESRD). The individual must have had both parts A and B coverage from
12 months prior to diagnosis month until 12 months post diagnosis month (or until death) without
HMO coverage during this time period. This is to ensure that the claims data is available for both
inpatient and outpatient services. It also enables calculation of a comorbidity index for preexisting
conditions. The inclusion criteria for this study are broad with respect to disease characteristics.
This will permit examining both indicated as well as contraindicated use of SLNB. It also provides
more information to base the models upon in comparison to sub-setting to some smaller popula-
tion. Definitive treatment must have occurred within 12 months of diagnosis. This is necessary in
order to be able to identify the institution where a SLNB may have been performed. After all cri-
teria were applied there were 76478 patients included in the analysis and 2030 institutions where
they received treatment.
Concluding this section is a description of the variables used in this work.
Variables included in the modeling process
Region level
SEER region, with rural GA andAtlanta combined, is a fixed effect. Time (month of diagnosis),
scaled to 0 to 1 from start of study period, January 1999 to end of study period December 2007,
Time2, and Time3, are fixed effects at the region level.
Hospital level
The continuous time variables are random effects at the hospital level. There were three hospi-
tal level fixed effects: ACOSOG, an indicator variable for institutional affiliation with the American
College of Surgeons Oncology Group, a sponsor of a SLNB clinical trial, Co-op group, an indica-
tor variable for other NCI cooperative groups having breast cancer research portfolios including;
National Surgical Adjuvant Breast and Bowel Project, Cancer and Leukemia Group B, Southwest
Oncology Group, and the Eastern Cooperative Oncology Group, and Teaching Hospital, an indi-
cator variable for medical school affiliation. The interaction with the linear effect of time for all
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hospital level fixed effects was also examined.
Person level
Demographics
There were three demographic person level fixed effects: Race being African American (AA),
an indicator variable, with the reference group being all other races, Age, a categorical variable of
patient age at diagnosis, with levels of: 66 to 69 (which is the reference group), 70 to 74, 75 to
79, and 80 plus, and Medicaid, an indicator variable for the patient being dual eligible during the
year of diagnosis, a proxy for individual low income status. The interactions of the person level
variables were explored as well as interactions with the linear effect of time.
Disease and treatment variables
Disease characteristic variables included the fixed effects of: Tumor grade, a four level cat-
egorical variable with the reference being ‘well differentiated’ and three indicator variables for
the levels of ‘poorly differentiated’, ‘moderately differentiated’, and ‘unknown or not assessed’,
Tumor size, we transformed the two continuous size variables (there are two due to a change in
coding systems over time) into T staging categories from AJCC TNM staging. The reference cat-
egory was T1c. This was the only staging variable used as it is the only constant staging data over
time with changes in systems occurring during the timeframe of this study. Additionally, we do
not know whether the N staging reported was clinical or pathologic, presumably for those who
received nodal staging it was pathologic, while for those where there was no indication of staging
it is unclear. Thus an inaccurate assessment of the effect of N staging is a concern, given that
treatment decisions at that point in treatment are based upon the clinical results. The interaction
between tumor grade and size was also included.
Treatment variables included surgery type and receipt of SLNB. Surgery was a three level cate-
gorical variable for the receipt of breast conserving surgery (BCS) and or mastectomy with the
reference category being BCS only. The other two levels were mastectomy only and both BCS and
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mastectomy. It was hypothesized that various factors that would influence surgery type (and sub-
sequent surgeries) would also influence the use of SLNB. Receipt of SLNB (0,1) was the outcome
variable and based upon both claims and registry data.
2.2.2 Proposed Model
The proposed model is a three level mixed effects logistic normal model with random intercept
and cubic polynomial of time at the second level for the systematic component.
Let Y be the response vector of lengthN consisting of zeros and ones indicating each patients
(non)receipt of SLNB. pi (X,Z, γ) is a vector of length N consisting of the expected value of Y ,
that is, the probability of the receipt of SLNB for each patient. η is a vector of lengthN consisting
of the log odds. X is the design matrix with variables at the patient, hospital, and region levels.
β is the set of parameter values associated with the respective variables in the design matrix. Z
is a subset of X consisting of the design matrix for the random effect variables, in this case the
polynomial of time at the second, hospital, level. γ is the random effect matrix.
The general form of the systematic component of this model is:
η = logit (E(Y |γ)) =Xβ +Zγ (2.1)
While the error function is:
Y |γ ∼ Bern(pi) where Ys ⊥ Yt and s 6= t (2.2)
Note that:
Z = [1, time, time2, time3] (2.3)
and
γ ∼ MVN4(0,G) (2.4)
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LetN be the total number of patients observed in theM hospitals in theL regions. Each patient
is observed only once and they are assumed to be i.i.d. within a hospital and over time conditional
upon the patient, hospital, and regional covariates. There are L third level units, regions, which are
indexed by k such that k = 1 to L. There are nk second level units, hospitals, in each third level









The three levels of the systematic component are:
ηijk = α00jk + x
(10)⊺
ijk α01jk + x
(11)⊺
ijk α1jk (2.6)
α00jk = β00k + x
(2)⊺
jk β01k + γ
(2)
0jk (2.7)
α1jk = β10k + x
(2)⊺
jk β11k + γ
(2)
1jk (2.8)
β00k = λ00 + x
(3)⊺
k λ01 (2.9)





ijk is a vector of length p whose elements consist of first (patient) level explanatory variables.
For notational convenience it is broken out into x
(10)
ijk consisting of the demographic and disease




ijk which consists of a cubic of time. Time corresponds to the patient’s diagnosis
month relative to the start and end of the study (normalized to a value between 0 and 1). Note that
the patient level variables (other than time) are stochastic and time varying in this context relative
to the higher levels. It is assumed that their values at any given time point are not related to the
outcome values of other patients at prior time points. x
(2)
jk is a vector of length q whose elements
consist of second (hospital) level explanatory variables which may be time varying. x
(3)
k is a vector
of length r whose elements consist of third (region) level explanatory variables.
Equations 2.6 to 2.10 can be expressed as a single equation:
ηijk =λ00 + x
(3)⊺
k λ01 + x
(2)⊺






















Where the fixed effect intercept terms are on the first line of equation 2.11, the fixed ‘slope’
terms are on the second line, and the random intercept and slope is on the third line. Thus from the
first line, λ00 is the overall intercept, x
(3)⊺
k λ01 are the regional deviations from the overall intercept,
x
(2)⊺
jk β01 are hospital characteristic deviations from the overall intercept, and x
(10)⊺
ijk α01jk are patient
level deviations from the overall intercept. From the second line we respectively, the overall slope,
the regional deviations from the overall slope, and the hospital characteristics deviations from the
overall slope. The random effects in the third line represent hospitals deviations from the overall
intercept and slope since we are assuming that the random effects distributions are the same for all
regions.
Concluding the methodology section is a description of the modeling process.
2.2.3 Modeling Process
A forward and reverse stepwise modeling process was used to obtain the best fitting model
for this set of data. The decision criteria for retaining variables in the model were chosen as to
not over fit the model and with an eye towards parsimony. Likelihood ratio tests were performed,
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when appropriate, with the decision criteria of retaining terms whose inclusion generated either a
p-value of less than .001 or an improvement in the BIC otherwise.
Preliminary models, looking at the time and random effects specification, started with a simple
logistic regression of the use of SLNB with the fixed effect terms of SEER region and a set of
indicator variables for time (year) and no other terms in the model. Next was a similar model
except for using a cubic polynomial of time instead of the year indicator variables. The third
model looked at separate cubic polynomials for each SEER region. The next tested the need for a
random intercept of hospital(region). The last three models in the preliminary analysis added the
random terms of time, time2, and time3 respectively, all with unstructured covariance matrices.
We then proceeded to build a model based on the random effect specification of a cubic poly-
nomial of time with an unstructured covariance matrix for hospital(region). These models added in
a stepwise fashion, the fixed effects of disease characteristics, surgery type, patient demographics,
and institutional characteristics. Finally a reverse modeling process was employed to determine
which variables interacted with linear time and the best fitting model was kept as the final specifi-
cation of the fixed effects.
To confirm the appropriateness of the random effects specification a reverse process was used
and four additional models were created that sequentially removed the highest order random effect
term from the preceding model.
2.3 Results
2.3.1 Model Fitting Results
The results of the preliminary model fitting process are shown in Table 2.1. It includes the val-
ues for each model of: -2×loglikelihood (-2LL), the likelihood ratio test significance (LRT), when
applicable, for comparing the model to the preceding model, and the model Bayesian Information
Criteria (BIC). The number of asterisks in the LRT column correspond to p-values of less than
0.05, 0.01, and 0.001.
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The results indicate that relative to the standard (and each subsequent) model there are incre-
mental improvements by: using a cubic polynomial of continuous time, having separate polyno-
mials for each SEER region, including a random intercept for hospital, including a random linear
effect of time, including a random quadratic of time, and including a random cubic of time. In
each case (where applicable) the LRT had a p-value of less than 0.001. In the cases where the LRT
was not applicable there was an improvement in the BIC.
Table 2.1: Preliminary Model Fit Statistics
Model Description -2LL LRT BIC
GLM 1 Fixed effects of Region with categorical time 91103 NA 91373
GLM 2 Fixed effects of Region and cubic of time 90975 NA 91178
GLM 3 Fixed effects of Region interacted with cubic of time 90756 *** 91262
GLMM 0 GLM 3 + Random intercept for hospital(region) 82568 NA 82918
GLMM 1 GLMM 0 + Random linear time 81677 *** 82156
GLMM 2 GLMM 1 + Random quadratic time 81427 *** 81930
GLMM 3 GLMM 2 + Random cubic time 81356 *** 81889
Table 2.2 shows the results for the forward stepwise model building process for the proposed
fixed effects. All of the proposed main effects were found to improve the model fit with p-values
of less than 0.001. The interaction of tumor size and tumor grade was found to be significant
(p<0.001). The only demographic interaction found to be significant (p<0.05, with an improve-
ment in the BIC) was between age and Medicaid status. The interactions of the hospital covariates
were not included as they did not meet the inclusion criteria. The only interaction with time found
to be significant (p<0.001) was that with the set of hospital covariates.
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Table 2.2: Model Fit Statistics for Significance of Fixed Effects
Model Description -2LL LRT BIC
GLMM 4 GLMM 3 + Tumor size and grade 77841 *** 78450
GLMM 5 GLMM 4 + Tumor size grade interaction 77711 *** 78503
GLMM 6 GLMM 5 + Sugery type(s) 76554 *** 77361
GLMM 7 GLMM 6 + Demographics 74651 *** 75496
GLMM 8 GLMM 7 + Hospital covariates 74442 *** 75310
GLMM 9 GLMM 8 + Demographic interactions 74426 NS 75371
GLMM 10 GLMM 8 + Age by Medicaid interaction 74432 * 75323
GLMM 11 GLMM 10 + Hospital covariate interactions 74416 ** 75338
GLMM 12 GLMM 10 + Hospital covariates by time 74381 *** 75295
Table 2.3 shows the results for the confirmation of the necessity of the random effects terms.
These results were based on a reverse stepwise process with GLMM 13 being compared to GLMM
12, GLMM 14 being compared to GLMM 13, and so on. The results indicate that all random
effects terms were highly significant (for the nested models) with p-values less than 0.001 and that
excluding the random intercept substantially increased the BIC. Given the confirmation of the best
fitting model including the cubic polynomial of time in the random effects, GLMM12 was selected
as the final model.
Table 2.3: Model Fit Statistics for Significance of Random Effects
Model Description -2LL LRT BIC
GLMM 13 GLMM 12 without random cubic of time 74476 *** 75337
GLMM 14 GLMM 13 without random quadratic of time 74742 *** 75580
GLMM 15 GLMM 14 without random time 75531 *** 76353
GLM 4 GLMM 15 without random intercept 81947 NA 83151
In the next section we present the parameter estimates for the final model.
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2.3.2 Final Model Parameter Estimates
Parameter estimates for the best fitting model are presented for the fixed effects in Tables 2.1
to 2.6 and for the random effects in Table 2.7. We start with the fixed effects.
Fixed Effects
Table 2.4: SEER Region Parameter Estimates
SEER Region Intercept time time2 time3
1 - San Francisco -3.35 4.31 2.79 -2.78
2 - Connecticut -4.35 14.24 -15.26 6.32
20 - Detroit -4.80 13.27 -14.89 7.86
21 - Hawaii -4.09 6.38 -0.88 -0.12
22 - Iowa -5.29 10.65 -4.70 0.08
23 - New Mexico -3.31 2.38 10.23 -8.38
25 - Seattle -2.98 11.24 -8.39 1.60
26 - Utah -3.44 2.64 9.93 -8.05
27 - Atlanta and 37 - Rural Georgia -3.83 9.94 -6.94 1.80
31 - San Jose -3.09 5.31 2.46 -3.48
35 - Los Angeles -3.79 10.55 -10.26 4.10
41 - Greater California -3.29 6.40 -0.14 -1.84
42 - Kentucky -4.00 11.56 -11.44 5.08
43 - Louisiana -3.29 4.64 1.25 -1.81
44 - New Jersey -3.25 9.83 -9.28 3.80
Table 2.5: Tumor Characteristics Parameter Estimates
Tumor Grade/Size T1mic T1a T1b T1c T2 T3/4 Unkown
Well Differentiated -1.07 -0.27 0.04 0.00 -0.33 -0.81 -1.33
Moderately Differentiated -1.12 -0.53 -0.05 -0.01 -0.46 -1.21 -1.48
Poorly Differentiated -0.71 -0.71 -0.30 -0.22 -0.62 -1.61 -1.67
Undifferentiated -1.24 -1.54 -1.30 -1.14 -0.93 -1.41 -1.70
Unknown, Not Assesed -0.94 -1.06 -0.87 -0.52 -0.68 -1.21 -1.85
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Table 2.6 gives parameter estimates for the final model treatment, demographic, and hospital
variables. Note that these are on the log odds scale as the presence of interactions would require
calculations at specific levels to give meaningful odds ratios for most of the effects. The baseline
group for this model is patients who: were non African American, received BCS only, had a well
differentiated tumor, whose tumor size was T1c, were of age of 66 to 69 at diagnosis, not on med-
icaid, and whose hospital had no affiliations.
Thus relative to this group we can see that receipt of mastectomy, whether as the first surgery or
subsequent surgery, led to a decrease in the odds of receipt of SLNB. Likewise for African Amer-
icans. For older women and those on Medicaid the story is a little more complicated given the
significant interaction. The interaction can however, be interpreted as either an additional increase
in the (negative) effect of age for those on Medicaid or an additional (negative) effect of Medicaid
for older patients. Receiving treatment at a teaching hospital, at cooperative group affiliated hos-
pital, and particularly an ACOSOG affiliated hospital, early in the time period examined, led to a
increase in the odds of receipt of SLNB. Although this increase in odds diminished over the course
of the study with the teaching hospital and ACOSOG effects being reduced to almost nothing. In-
terestingly, the cooperative group effect did not attenuate as much over time. Note that time effects
were examined for the patient level covariates in a separate model (data not shown) whose results
indicated that there was no change over time for the patient demographic variables.
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Table 2.6: Treatment, Demographic, and Hospital Variables Parameter Estimates
Effect Estimate Std. Error DF t p value
BCS Only 0.000 . . . .
Mastectomy Only -0.694 0.023 74346 30.23 <.0001
Both BCS and Mastectomy -0.597 0.032 74346 18.71 <.0001
African American -0.315 0.044 74346 -7.14 <.0001
65 to 69 0.000 . . . .
70 to 74 -0.058 0.029 3301 -2.00 0.0453
75 to 79 -0.174 0.029 3301 -5.92 <.0001
80 plus -0.905 0.029 3301 30.84 <.0001
On Medicaid -0.344 0.061 74346 -5.62 <.0001
65 to 69 on Medicaid 0.000 . . . .
70 to 74 on Medicaid -0.111 0.082 74346 -1.35 0.1783
75 to 79 on Medicaid -0.269 0.085 74346 -3.14 0.0017
80 plus on Medicaid -0.142 0.084 74346 -1.70 0.0893
Teaching Hospital 0.334 0.132 74346 2.54 0.0111
Cooperative Group Affiliation 1.064 0.154 2014 6.89 <.0001
ACOSOG Affiliation 1.243 0.181 2014 6.85 <.0001
Teaching Hospital over time -0.330 0.176 74346 -1.88 0.0601
Cooperative Group over time -0.335 0.188 74346 -1.78 0.0756
ACOSOG over time -1.068 0.212 74346 -5.05 <.0001
Random Effects
Table 2.7 gives the random effects variance components estimates for the final model in bold.
The standard errors are in parentheses and the correlations are in the lower triangle of the matrix
in italics.
Table 2.7: Variance Component Estimates
Intercept Time Time2 Time3
Intercept 3.3 (0.5) -7.0 ( 2.5) 5.7 ( 5.0) -0.9 ( 3.0)
Time -0.43 82.9 (20.5) -159.1 (43.7) 84.7 (26.2)
Time2 0.17 -0.93 354.8 (95.4) -206.0 (57.8)
Time3 -0.04 0.83 -0.98 125.6 (35.2)
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2.3.3 Trajectories Based on Final Model
Figure 2.3 shows the trajectories for a typical hospital that has no affiliations in each SEER
region for patients with the reference values for the disease and demographic variables. These
trajectories are based on the fixed effect parameters of SEER region and their interactions with the
cubic polynomial of time.
Figure 2.4 shows the trajectories of five example hospitals within the San Francisco SEER
selected to demonstrate the amount of variability within a SEER region.
Figure 2.5 shows the trajectories for the different levels of variables that policy could presum-
ably impact within the San Francisco SEER regioin. For example hospitals could recieve incen-
tives to belong to a cooperative group or at risk populations could be targeted to help alleviate the


















































Figure 2.4: Trajectories of Sample Hospitals in San Francisco SEER Region
2.4 Discussion
The primary finding is that the Innovation Adoption Trajectories of SLNB do vary by institu-
tion and region as indicated by the the significance of the polynomial of time in the random and
fixed effects. Thus they are a potential candidate for the basis of quality metrics that measure the
adoption of evidence based procedures.
The utility of this type of model in comparison to standard models is three fold: it has the
capability of looking at hospital specific outcomes over time, it is more robust to missing data, and
it fits considerably better. Additionally, the estimates of the parameters and p-values should be
both more precise and more trustworthy based on theoretical considerations (51; 53).
Although no comparison was made to the GEE based population average model some consid-
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Figure 2.5: Effect of Policy Variables within San Francisco SEER Region
approach permits subject (hospital) specific estimates of the trajectories, something that is not pos-
sible with a GEE based approach. Another is that GEE based models depend on missing data being
MCAR, something that may not be true of SEER-Medicare data, while the GLMM only requires
MAR.
Previously reported disparities related to race and SES were found to continue throughout
the study period as there was no significant interaction with time for these variables. Previously
reported positive effects of NCI cooperative group affiliation were found to be present but their
effect attenuated over time as indicated by the statistically significant interaction with time for
these variables. It would seem that these affiliations were associated with a head start for those
institutions but the other institutions caught up by the end of the study period.
Whether institutional culture is impacted by these affiliations or whether the culture of early
adopter institutions drives having the affiliations can not be discerned by this associative study. It
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should also be noted that the basic assumptions (1) - (4), albeit reasonable, may not be always very
tenable, particularly when there are numerous covariables and when the assumption of multinor-
mality in (3) may be questionable. Possible departures from these model assumptions may affect
the p-values, particularly in the tail. This aspect needs to be studied in greater detail. Further
research could include looking at whether some other random effects distribution would provide
a better fitting model given the known sensitivity of the binary outcome GLMM to the random
effects distribution specification (21; 18; 34; 33).
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3 EVIDENCE BASED MEDICINE IMPLEMENTATION INDEX
3.1 Introduction
Clinical trial results enable evidence-based change in practice but their adoption may vary
by institution and region. Innovation adopter types were originally proposed by Rogers’ (1962)
in his theory of the diffusion of innovation. Rogers proposed five categories of adopter types,
innovators, early adopters, early majority, late majority, and laggards. He hypothesized that these
types comprised 2.5, 13.5, 34, 34, and 16 percent of the population respectively. This work extends
his original idea of the time until use of an innovation to a metric that characterizes the pattern of
the rate of use of an innovation over time.
In order for an institutional metric to be useful it should be easy to understand, be generalizable
among different conditions, control for case-mix, and allow fluctuation of caseload over time. To
meet these objectives we propose a two step process. First institutional trajectories of the rate of
use of an innovation are created that control for disease and patient characteristics. This is done by
use of a generalized linear mixed model (GLMM). Next, the area under the curve (AUC) of each
institution’s trajectory is calculated. Early adopters will have larger values of this metric while
those that adopt later will have smaller values.
As a test case for this metric, we considered the procedure of sentinel node biopsy (SLNB)
and its adoption among hospitals participating in the SEER-Medicare registry from 1999 to 2007.
Sentinel node biopsy is a surgical procedure adopted in the last 20 years as a less morbid alternative
to axillary lymph node dissection (ALND) for determining lymphatic spread of tumor in early
stage breast cancer. Prior to initiation of clinical trials of SLNB, standard of care for lymph node
assessment required an axillary lymph node dissection (ALND) which conferred over a 20% risk
of lymphedema and occasional long-term nerve injury.
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The introduction of SLNB in the mid 1990’s, followed by a growing body of level I and level
II evidence demonstrating equivalent accuracy as ALND for pathologically node negative cases
allowed SLNB to supplant ALND as the standard of care (62; 13; 52; 14; 41; 54; 55; 61; 56).
Medicare started reimbursing its use in 1999 while it was still in clinical trials since early evidence
suggested it was a preferred treatment option in many cases. With the conclusion of the clinical
trials SLNB became the documented standard of care for lymphatic staging of early stage breast
cancer (26).
We propose that variability in adoption of clinical trial results can be captured by quantifying
innovation adopter type. In this work we make the assumptions that institutions have consistent
cultures over time (albeit changeable) and that individual physicians both contribute to the culture
and in general follow the treatment patterns of the prevailing institutional culture.
3.2 Methods
3.2.1 Data Description
The data used to generate the models of trajectories of rate of use of SLNB in indicated cases
come from the NCI SEER-Medicare database, which is derived from 14 cancer registries covering
17 geographic regions across the US. Individual cases are linked to the corresponding Medicare
claims and eligibility information. For those cases where the first primary cancer occurred at an
age of 65 or greater there is a success rate of 94 percent in linking to Medicare data This data
source is described extensively elsewhere (59; 4; 25).
The patient-level inclusion criteria are that the Medicare recipient is female with her first or
only incident primary breast cancer occurring during the years of 1999 to 2007. A valid diagnosis
month must be present and the reporting source must not be autopsy nor death certificate. This
cancer must have occurred at age of 66 or later and the basis for Medicare coverage must not be
End Stage Renal Disease (ESRD). The individual must have had both parts A and B coverage from
12 months prior to diagnosis month until 12 months post diagnosis month (or until death) without
HMO coverage during this time period. This is to ensure that the claims data are available for both
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inpatient and outpatient services. The inclusion criteria for this study were broad with respect to
disease characteristics. This will permit examining both indicated as well as contraindicated use of
SLNB over time. Definitive treatment must have occurred within 12 months of diagnosis. This is
necessary in order to be able to identify the institution where a SLNB may have been performed.
Patients that received neoadjuvant chemotherapy are excluded from the analysis. In total, 74,516
patients met the inclusion criteria for this study with an associated 2,004 institutions where surgery
was performed.
At the hospital-level the inclusion criteria are that there must have been at least 15 cases that
met the patient-level inclusion criteria treated at that hospital during the time period of the study.
In order to be included in the final analysis all the hospital-level covariates needed to be present.
720 institutions were included after applying these criteria with 70,371 associated patients. Two
institutions had missing hospital-level covariates and were excluded from the final hospital level
analysis.
3.2.2 Use of GLMM to generate institutional trajectories
Generalized linear mixed models with a binary outcome are a standard way of generating tra-
jectories for outcomes such as treat/no treat or use of procedure A vs. procedure B when there are
either multilevel or longitudinal aspects to the data. It is an extension of logistic regression that
handles cases that violate several assumptions of simple logistic regression. Given that institutions
are routinely grouped by region or have registries they report to that service a particular region, as
well as the measurement of use of a procedure at the patient level, it is natural to use a multilevel
approach. Since we are interested in the rate of use of a procedure over time we also want to control
for the repeated measures (at the institution level) aspect of the data. They also have the advantage
that they handle missing or unbalanced data well given the assumption that data are missing at
random. This approach, however, does require the use of data from a population of institutions,
possibly from multiple regions in order to create the model.
Fixed effect terms in the multilevel longitudinal model included the SEER regions and their
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interactions with time. These estimate the trajectory of the the typical hospital in each region.
Additionally there were fixed effects for patient age and disease characteristics. Random effects
of time at the hospital nested within SEER region level provide estimates of how a hospital’s
trajectory varied from the typical hospital within the SEER region. The reference group used in
generating institutional trajectories consisted of T1/2, well-differentiated tumor, and aged 66 to 69.
3.2.3 AUC of trajectories
In using the AUC of trajectories to characterize adopter types we are assuming the trajectories
are non-decreasing functions over the time span considered. This would imply the ordering of the
AUC corresponds to the ordering of adopter type. The AUC of these model based trajectories is
not simply the average rate of use of the procedure, but a function that weights all time points
equally regardless of fluctuations in case load as well as controlling for case-mix.
The area under the curve of the trajectories was calculated based on the parameter estimates
from the GLMM. For SEER regions this was based on the fixed effects of region and region by the
cubic polynomial of time. For institutions they were based on the regional estimate plus (or minus)
the institution specific random effects estimate.
3.2.4 Institution level analysis
In general we are proposing that the Evidence Based Implementation Index (EMII) be a func-
tion of a set of procedures whose AUC’s are combined to form the metric. However, in this single
procedure proof of concept, further analysis was performed using the EMII based upon the single
procedure’s AUC. Hospital level covariates such as whether it was a teaching hospital and what
cooperative groups the institution was affiliated with were then examined to see if the EMII would
vary by membership status. Simple descriptive statistics of the EMII were generated overall and by
hospital characteristic. Additionally an ANOVA type approach was used, modeling the relation-
ship between institutional variables and the EMII. This was done to control for the effects of SEER
region and unequal cell sizes of the combinations of variables while estimating the magnitudes of




All terms in the model were highly statistically significant and used in calculating the EMII.
3.3.2 Regional trajectories
Trajectories of the SEER regions are based upon the fixed effects of the GLMM and in these
hospital specific models represent the trajectory of a hypothetical ‘typical hospital’ from the region.
Figure 3.1 shows these trajectories; the difference between adoption patterns is evident with Seattle




























Figure 3.1: SEER Regional Trajectories of the rate of use of SLNB
3.3.3 Institutional Trajectories
Institutional trajectories are based upon the combination of the relevant fixed effects (i.e. the
SEER region and its interaction with time) and the predicted random effect values for the cubic






















Figure 3.2: Trajectories of Sample Hospitals in San Francisco SEER Region
shown to demonstrate the variability found within a given region are shown in Figure 3.2
3.3.4 EMII
Region level values of the EMII are given in Table 3.1 in the ‘typical’ column. These represent
the EMII of a typical hospital in the SEER region. Note that the typical value may not be the same
as the mean value. The number of institutions included from each region in also given.
Table 3.1 also includes the mean, standard deviation, minimum, and maximum values at the
hospital level within each SEER region and overall. Graphical examination of all 720 institutions
indicates a bell shaped curve (data not shown). This would be consistent with Rogers’ theory of
a somewhat normal shaped distribution of adopter types. Table 3.2 gives the values for different
hospital characteristics. Note that these groups are not mutually exclusive.
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3.3.5 Model with EMII as outcome looking at hospital characteristics
The results of the exploratory analysis using the EMII as the outcome measure found that after
controlling for regional variations there was strong evidence (p< .01 for the system of variables)
that the variables of: ACOSOG affiliation, Teaching hospital, there being at least one Cooperative
group affiliation besides ACOSOG (One Plus), the interaction of Teaching hospital and One Plus,
and there being at least four cooperative group memberships other than ACOSOG (Four Plus), had
significant association with the EMII. The effects of One Plus and Four Plus are additive which
gives the net effect of there being three categories, no additional cooperative group memberships
(the base case), one to three additional cooperative group affiliations, and four plus.
Table 3.1: Descriptive statistics of the EMII overall and by SEER region.
SEER Region n Typical EMII Mean EMII Std. Dev. Min EMII Max EMII
San Francisco 27 42 46 17 9 76
Connecticut 34 56 56 13 29 81
Detroit 34 36 40 18 11 73
Hawaii 14 35 38 17 13 79
Iowa 69 35 38 20 7 86
New Mexico 23 33 37 23 10 84
Seattle 33 66 66 13 41 87
Utah 24 42 45 15 17 69
Atlanta 24 49 51 16 25 81
San Jose 15 48 50 20 15 72
Los Angeles 60 41 45 20 12 77
Greater CA 152 45 48 19 4 87
Kentucky 60 40 43 18 14 82
Louisiana 64 35 39 22 7 86
New Jersey 87 47 49 18 11 83
ALL 720 46 20 4 87
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Table 3.2: Descriptive statistics of the EMII by hospital characteristics
Characteristic n Mean EMII Std. Dev. Min EMII Max EMII
No affiliations 282 37 19 4 86
ACOSOG 111 59 16 16 87
NCI Comprehensive
Cancer Center 21 68 12 46 85
Teaching Hospital 284 51 19 8 87
1 to 3 Co-op Groups
(other than ACOSOG) 261 51 17 10 86
4 or more Coop Groups
(other than ACOSOG) 91 60 16 16 87
There was also moderate evidence (p=.07) that NCI comprehensive cancer centers had an ad-
ditional effect upon the EMII beyond the effect of teaching hospital, ACOSOG, and number of
cooperative group memberships. All of these institution level variables were associated with an
increase in the EMII except for the interaction of Teaching Hospital and One Plus which was neg-
ative and indicated that the effect of One Plus was less for Teaching Hospitals than Non-Teaching
Hospitals. Table 3.3 gives the estimated model adjusted values of the EMII for each region and
their standard errors. Note that the region-level estimates correspond to the case where the institu-
tion is not a teaching hospital and has no affiliations. Table 3.4 gives the estimated effects of the
institutional-level variables and their standard errors and p-values.
3.4 Discussion
We have demonstrated that the EMII differentiates uptake of new procedures (specifically,
SLNB) among regions and institutions as well as between different hospitals types and institutional
affiliations. While it doesn’t show cause and effect, it provides a method to quantify which regions
and types of institutions are early adopters of clinical trial results. This information, if made
available, could be used by patients to select service providers (early adopters) as well as to drive
institutional behaviors for early adoption.
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Table 3.3: Estimated EMII values by region for non affiliated hospitals
SEER Region Estimate Std. Err.









San Jose 42 4
Los Angeles 36 2
Greater CA 42 2
Kentucky 36 2
Louisiana 35 2
New Jersey 37 2
Table 3.4: Institutional affiliation estimated effects
Effect Estimate Std. Err. p-value
ACOSOG 7 2 .0015
Teaching Hospital 5 2 .022
Plus One 12 2 <.0001
Teaching Hospital*Plus One -7 3 .025
Plus Four 6 2 .013
NCI Comprehensive CC 8 4 .070
In the United States, more than $3 billion are spent in clinical trials research annually by the
NIH alone, and these studies are only meaningful in their ability to change clinical practice and
improve outcomes on a wide scale. Reasonable concerns that trials may yield positive results but
nevertheless fail to drive practice change likely impact both current and future federal resource
allocation into clinical trials. Prime examples of this may be found in prevention studies: NSABP
P01 discovered almost a 50% reduction in breast cancer incidence with 5 years of tamoxifen use.
However, this has not led to an increased uptake in chemoprevention, even 15 years after these
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results were first reported. The reason underlying the low uptake is multifactorial, but an instru-
ment such as the EMII could be of importance in tracking, reporting, and encouraging widespread
adoption of clinical trials findings shown with a high level of evidence to likely to positively impact
human health.
There are some important limitations of the study which merit discussion. First, the data we
analyzed were limited to an older Medicare population so that its relevance to younger patients
requires further testing. Moreover, there could be indications for and against use of the sentinel
node biopsy procedure in individuals which may be difficult to capture. One example of this is in
those women who were candidates for sentinel node biopsy, but in whom age and comorbidities
were clinically deemed to preclude additional surgical procedures. One way in which this could
be addressed is to evaluate the proportion of patients receiving axillary staging by ALND versus
SLNB rather than evaluating the rate of SLNB uptake alone. However, this could create an ad-
ditional confounder in that women with obviously positive nodes at diagnosis would be correctly
treated with ALND instead of SLNB and thus not represent poor uptake of SLNB. Such issues will
require individual consideration for each procedure measured. Nevertheless, this study provides
an indication of how such a metric may be constructed, in the older Medicare population which
carries the greatest cancer burden.
Further research is clearly needed to see if this approach holds across different procedures and
different disease types as well as for populations other than Medicare patients. If to be used as a
quality metric, benchmarks would need to be generated in order to assess where an institution is at
in its process of adopting evidence based medicine. Finally, although it is assumed that the use of
evidence based medicine improves outcomes, the correspondence between this metric and actual
outcomes must be assessed.
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4 ESTIMATION OF VARIANCE COMPONENTS
4.1 Introduction
In the previous two chapters we have seen that a Logistic Normal Mixed Model (LNMM) can
be useful in characterizing the adoption trajectories of Sentinel Lymph Node Biopsy (SLNB) of
hospitals serving women on Medicare with breast cancer using SEER-Medicare data. However
it has been assumed that the use of Maximum Likelihood (ML) Estimators of the variance com-
ponents of the random effects is preferable in contrast to pseudo-likelihood (PL) estimators. One
reason for this assumption is that it has been shown that in a LNMM the PL estimator leads to
biased results for the fixed effects (6; 32). ML with quadrature based estimation has been shown
to have the least bias, while ML with Laplace estimation is somewhere in between (43).
One aspect that has not been considered previously is whether the bias inherent in the PL
estimators could be reduced by use of a jackknife approach (16). Nor has the relative efficiency
(23) of the estimators been compared in a LNMM. In order to investigate these aspects, a model
employing random intercept and slope terms (and their covariance) was created with the subject
being hospital nested within SEER region. It is assumed that patients are i.i.d. after controlling
for all other factors and that any change over time in a hospital’s use of SLNB is due to changes
in physician/hospital practice rather than changes in the patient population. In order to increase
precision, stratification by number of patients a hospital treated over the course of time the data
covered (1999 to 2007) was performed.
Two types of PL estimators were considered, Maximum Subject Specific PL (MSPL) and Re-
stricted Subject Specific PL (RSPL). MSPL (and it’s stratified jack knifed version) was included as
it’s results might be more comparable to the ML estimator. RSPL was included as it is frequently
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used. Random effects covariance matrix estimator efficiency was compared via A-, D-, and E- ef-
ficiency metrics which permitted multivariate comparisons in efficiency between ML and the four
other estimator types, MSPL, RSPL, stratified jackknifed MSPL and stratified jackknifed RSPL.
By use of the efficiency metrics we can quantify overall differences in the covariance matrices with
respect to the stated precision of the estimates.
4.2 Methods
Five estimators were used to estimate the variance components of a LNMM with random in-
tercept and slope at the second level of a three level heirarchical model. The dataset used was
SEER-Medicare data which is briefly described in the next section.
4.2.1 Data
The data used to generate the models of trajectories of rate of use of SLNB in indicated cases
come from the NCI SEER-Medicare database, which is derived from 14 cancer registries covering
17 geographic regions across the US. Individual cases are linked to the corresponding Medicare
claims and eligibility information. This data source is described extensively elsewhere (59; 4; 25).
A quick overview of SEER-Medicare data methodology follows.
Selected SEER registry data elements (those elements with known poor reliability are ex-
cluded) from each incident cancer diagnosis, up to the first ten, are put into a format of one record
per person. This data is then linked to Medicare eligibility data and a 94% linkage rate has been
found for cases where the first cancer occurred at an age of 65 or greater. Cases where there is a
successful link are kept.
This information is combined with demographic and eligibility information from the Medicare
program to create the Patient Entitlement and Diagnosis Summary File (PEDSF) file. The name is
a little misleading as it includes all of the (selected by NCI) SEER data, not just the diagnosis infor-
mation. It also includes (de-identified and ‘fuzzed’) census tract and zip code level demographic
(census) information.
Fixed effect eariables used in the modeling process included SEER region, time (scaled 0 to 1
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over the range of the data), SEER region by time, an indicator variable for institutional affiliation
with the American College of Surgeons Oncology Group, a sponsor of a SLNB clinical trial,
an indicator variable for other NCI cooperative groups having breast cancer research portfolios
including; National Surgical Adjuvant Breast and Bowel Project, Cancer and Leukemia Group
B, Southwest Oncology Group, and the Eastern Cooperative Oncology Group, and an indicator
variable for medical school affiliation. Interactions with the linear effect of time for all hospital
level fixed effects were also included.
There were three demographic person level fixed effects: Race being African American (AA),
an indicator variable, with the reference group being all other races, Age, a categorical variable of
patient age at diagnosis, with levels of: 66 to 69 (which is the reference group), 70 to 74, 75 to 79,
and 80 plus, and Medicaid, an indicator variable for the patient being dual eligible during the year
of diagnosis, a proxy for individual low income status.
Disease characteristic variables included the fixed effects of: Tumor grade, a four level cat-
egorical variable with the reference being ‘well differentiated’ and three indicator variables for
the levels of ‘poorly differentiated’, ‘moderately differentiated’, and ‘unknown or not assessed’,
Tumor size, we transformed the two continuous size variables (there are two due to a change in
coding systems over time) into T staging categories from AJCC TNM staging. The reference cat-
egory was T1c. This was the only staging variable used as it is the only constant staging data over
time with changes in systems occurring during the timeframe of this study. Additionally, we do
not know whether the N staging reported was clinical or pathologic, presumably for those who
received nodal staging it was pathologic, while for those where there was no indication of staging
it is unclear. The interaction between tumor grade and size was also included.
Treatment variables included surgery type and receipt of SLNB. Surgery was a three level
categorical variable for the receipt of breast conserving surgery (BCS) and or mastectomy with
the reference category being BCS only. The other two levels were mastectomy only and both
BCS and mastectomy. It was hypothesized that various factors that would influence surgery type
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(and subsequent surgeries) would also influence the use of SLNB. Receipt of SLNB (0,1) was the
outcome variable and based upon both claims and registry data.
In the next section the specification of the LNMM is given.
4.2.2 Logistic Normal Mixed Model
In this section we will use the following specification of the Generalized Linear Mixed Model.
Note that g−1 is the inverse link function and Z is the design matrix for the random effects.





V ar(Y |b) comes from the exponential family
For the LNMM:
Let N be the total number of patients observed. There are n hospitals (clusters) and i is the
index for the hospitals so that i = 1 to n. j indexes the patients within a hospital and there are mi
patients in the ith hospital, so j = 1 to mi. The response vector Yi = (Yi1, . . . , Yimi)
T consists of
zeros and ones that indicate each patients (non)receipt of SLNB.
Error distribution Yij ∼ Bern(piij)





The next section describes the use of Pseudo-Likelihood in variance parameter estimation.
62
4.2.3 Variance Parameter Estimation - Pseudo-Likelihood
The use of Pseudo-likelihood for estimation of variance parameters in a GLMM was proposed
in two separate papers in 1993 (5; 63). Both approaches make use of the generalized mixed model


















Where y∗, the ‘pseudo-data’, is alternately used to estimate β and b and is estimated using
their estimates from the previous iteration.
The following description of the ML estimation procedure draws heavily on the SAS docu-
mentation (47) for the procedure used to fit the models, Proc GLIMMIX (see chapter 38).
4.2.4 Variance Parameter Estimation - Maximum Likelihood with quadrature
The joint probability density function, in general, is given by:
f (Yi|Xi,bi) f (bi)




f (Yi|Xi,bi) f (bi) dbi
A two step procedure is used to get the maximum likelihood estimates, first obtain estimates
for β andG based on the marginal likelihood, using adaptive quadrature numerical integration for














where p (x) is a probability density function, f (x) is some function to be integrated against
it, Q is the number of quadrature points, r is its index, and wr are the quadrature weights. In
our case f (x) is the conditional distribution given the random effects, and p (x) is the random
effects distribution. When the number of quadrature points is not specified ahead of time then
Proc GLIMMIX determines the number of quadrature points by evaluating the log likelihood at an
increasing number of points until a tolerance is met. Additionally, and separately, ‘the procedure
centers and scales the quadrature points by using the empirical bayes estimates (EBEs) of the
random effects and the Hessian matrix from the EBE suboptimization.’ The manual goes on to
state that this process improves the likelihood approximation ‘by placing the abscissas according
to the density function of the random effects.’
The next section describes the jackknife procedure.
4.2.5 Jackknife procedure
In general, the jackknife estimator (16) is derived as follows: θˆn(4.1) is the estimator based
upon all the data, in our case Xk is the data from all the patients in the k
thhospital. θˆin−1(4.2)
are the estimators based upon the data less the ith element, θˆiJ (4.3) are the pseudovalues of the
jackknife, and θˆJ (4.4) is the jackknife estimator.
θˆn = θˆ (X1, . . . ,Xn) (4.1)
θˆin−1 = θˆ (X1, . . . ,Xi−1,Xi+1, . . . ,Xn) (i = 1, . . . , n) (4.2)












In the next section the stratification of the data that was done is described.
4.2.6 Stratified sampling
In order to reduce bias and to provide estimates for different size hospitals we have subdivided
the data into three strata. The strata are: small institutions with 1 to 49 patients in the data, medium
institutions with 50 to 199 patients in the data, and large institutions with 200 or more patients in
the data. Respectively there are s, m, and l institutions in the strata and they are indexed by o, p,
and q. Thus we have θˆJs, θˆJm, and θˆJl (4.5) as our jackknife estimators for the three strata. We
























In the next section the derivation of the jackknifed asymptotic covariance matrix is considered.
4.2.7 Jackknifing the asymptotic covariance matrix
At this point we note that there are two ways to derive the jackknifed asymptotic covariance
matrix. The first is to define θˆ as the estimator of the covariance matrix and calculate υJ (4.6) using














The other is to define θˆ as the estimator of the asymptotic covariance matrix,υˆ,and get the jack-
knifed estimator directly. This however calls for a modication of (4.3) and thus (4.4) to (4.8) and
(4.9) via the transformations in (4.7). Note that r in (4.7) is the number of fixed effect parameters
in the model and that we are essentially treating υˆn as the MSE in a regression model while υˆ
∗
n













υˆ∗iJ = (n− r) υˆ∗n − (n− r − 1)υˆ∗in−1 (i = 1, . . . , n)















Having done this for each of the three strata, we obtain a pooled optimally weighted estimate












The next section reviews estimation of multivariate relative efficiency.
4.2.8 Efficiency of Estimators
This section draws on section 8.6 of Jureckova, Sen, and Picek (2011) (23) where they discuss
multivariate efficiency. In all three types of relative efficiency we will consider the reference is
the ML estimator and it is the fisher information from that which is compared to the asymptotic
covariance matrix of the estimated random effects variance terms from the estimator which is under
consideration. Essentially each type of efficiency is a different statistic of the eigenvalues of the
product of asymptotic covariance matrix and the MLE fishers information. The specifics follow.
Let Tn be the estimator of interest of parameter θ, in our case the covariance matrix of the
random effects, and let υT be the dispersion matrix of Tn − θ. Let I(θ) be the Fisher information
matrix andD0 is the diagonal matrix of the p eigenvalues of υTI(θ).
Then we have:
D-efficiency
is the pth root of the determinant of (D0)−1 and is the geometric mean of the eigenvalues.
A-efficiency
is the mean of the eigenvalues of (D0)−1 and is the arithmatic mean. It will always be equal to
or greater than the value for the D-efficiency.
E-efficiency
is the largest eigenvalue of (D0)−1 and will always be larger than both the D- and A-efficiency
values.
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4.2.9 Relative efficiencies to be calculated
The two types of pseudoliklihood we will be considering are Maximum Subject Specific Pseu-
dolikelihood (MSPL) and Restricted Subject Specific Pseudolikelihood (RSPL). We will caclulate
both jackknifed and unjackknifed versions of their D, A, and E relative efficiencies. Note that for
both the non-jackknifed and the jackknifed estimates we use a pooled Fisher’s information matrix
(4.12).
I(θ)P = I(θ)s + I(θ)m + I(θ)l (4.12)
Thus we end up with four sets of efficiencies stemming from: ΛMSPL,ΛRSPL which are based
on the non-jackknifed and pooled constituent elements, and ΛJ−MSPL,ΛJ−RSPL which are based
upon the jackknifed and pooled estimates.
4.3 Results
In the following two sections the estimates for the the values of the covariance matrix for each
estimation type and the relative efficiencies will be given. We start with the covariance matrix
parameter estimates for both the overall models as well as the stratified and jack knifed models.
4.3.1 Parameter Estimates
Table 4.1 gives the variance and covariance estimates for each of the estimation methods: Max-
imum Likelihood (ML), Maximum Subject Specific Pseudolikelihood (MSPL), Restricted Subject
Specific Pseudolikelihood (RSPL), RSPL jack knife (JK), and MSPL jack knife. The standard
errors are also provided for the non-jack knife estimation methods. The jack knife based estimates
stem from the hospital group averages weighted by the number of hospitals in the group.
The intercept variance term estimates range from 1.98 to 2.49. The covariance term estimates
range from -1.36 to -1.69. The slope variance term estimates range from 2.05 to 2.41. For the
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intercept and the covariance estimates ML had the largest absolute values, while MSPL JK had the
smallest absolute values. For the slope estimate RSPL JK had the largest estimate while MSPL
had the smallest estimate.
Table 4.1: Covariance parameter estimates
Variable ML Std Err MSPL Std Err RSPL Std Err RSPL JK MSPL JK
Intercept 2.49 0.21 2.04 0.15 2.11 0.16 2.13 1.98
Covariance -1.69 0.20 -1.45 0.16 -1.51 0.16 -1.53 -1.36
Slope 2.28 0.23 2.05 0.20 2.17 0.22 2.41 2.12
Table 4.2 gives the variance and covariance estimates for each of the estimationmethods broken
out by hospital group (strata). The number of hospitals (M) and patients (n) are given for each
group. For ML there was a downward trend in the absolute value of the parameter estimates going
from the hospitals with the fewest patients in the data to the hospitals with the most patients in
the data. The two PL estimators had the smallest parameter estimates in the hospital group with
the most number of patients with the midsize group having the highest values. Comparing the ML
estimates to the PL estimates we find that in the ‘1 to 49’ group the ML estimates were noticeably
larger than the PL estimates. In the ‘50 to 199’ group the estimates were similar across the five
estimator types. In the ‘200+’ group the ML and the MSPL estimates were similar while the RSPL
estimates were somewhat higher. The combined estimates from the three strata shown in table
4.4 are based upon a weighting scheme using the inverse of the variance for each group and the
number of hospitals.
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Table 4.2: Covariance parameter estimates by hospital group
Group M n Variable ML Std Err MSPL Std Err RSPL Std Err
1 to 49 1624 12738 Intercept 3.11 0.47 2.01 0.26 2.15 0.28
Covariance -2.04 0.52 -1.33 0.33 -1.49 0.35
Slope 3.49 0.75 2.16 0.50 2.46 0.54
50 to 199 323 33291 Intercept 2.35 0.26 2.15 0.23 2.34 0.26
Covariance -1.85 0.26 -1.69 0.23 -1.87 0.26
Slope 2.37 0.31 2.20 0.29 2.46 0.32
200+ 99 30441 Intercept 0.89 0.15 0.87 0.14 1.10 0.20
Covariance -0.81 0.17 -0.79 0.16 -1.02 0.22
Slope 1.18 0.22 1.15 0.22 1.51 0.30
Table 4.3: Asymptotic covariance matrices by hospital group
Group Variable MLE MSPL RSPL
1 to 49 Intercept 0.217 -0.208 0.180 0.070 -0.075 0.076 0.077 -0.084 0.086
Covariance -0.208 0.268 -0.311 -0.075 0.110 -0.144 -0.084 0.124 -0.164
Slope 0.180 -0.311 0.567 0.076 -0.144 0.255 0.086 -0.164 0.291
50 to 199 Intercept 0.068 -0.060 0.051 0.054 -0.048 0.041 0.066 -0.059 0.051
Covariance -0.060 0.067 -0.070 -0.048 0.055 -0.058 -0.059 0.067 -0.072
Slope 0.051 -0.070 0.098 0.041 -0.058 0.083 0.051 -0.072 0.103
200+ Intercept 0.022 -0.022 0.022 0.021 -0.020 0.020 0.039 -0.038 0.038
Covariance -0.022 0.027 -0.033 -0.020 0.026 -0.031 -0.038 0.048 -0.058
Slope 0.022 -0.033 0.050 0.020 -0.031 0.048 0.038 -0.058 0.089
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Table 4.4: Covariance parameter estimates combined across groups
Variable ML MSPL RSPL
Intercept 2.30 1.87 2.09
Covariance -1.68 -1.33 -1.53
Time 2.47 2.01 2.35
4.3.2 D-, A-, and E-Efficiency Estimates for MLE vs. MSPL and RSPL
Table 4.5 shows the D-, A-, and E-efficiencies for the four pseudolikelihood based estimators
relative to MaximumLikelihood. The Jackknifed RSPL values are the lowest, ranging from 0.68 to
0.75, followed by the RSPL values ranging from 0.79 to 0.86, and the two non-jack knifed versions
being noticeably greater then the respective jack knifed estimators.
Table 4.5: D-, A-, and E-efficiency estimates
Type RSPL MSPL J-RSPL J-MSPL
D 0.792 1.190 0.682 0.839
A 0.793 1.191 0.683 0.843
E 0.860 1.270 0.754 0.912
Given the similarity of the D and A efficiencies an example case seems in order. Looking at the
MSPL eigenvalues we have (1.135, 1.167, and 1.270). Plugging these values into the respective
formulae for the three efficiency types as shown in section 4.2.8 we get the results as seen in Table
4.5.
4.4 Discussion
In this study we considered five different estimators of the covariance parameters in a LNMM.
We looked at the overall estimates of the parameters, the stratified estimates, the combined strati-
fied estimates and their relative efficiencies. While there were some differences across the overall
estimates the most striking differences were found across the three strata. These differences were
both in the parameter estimates and in the standard errors of the estimates. The differences in the
parameter estimates across strata indicate that the larger institutionswere more similar to each other
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than the smaller institutions. The differences in the standard errors, particularly for the smaller in-
stitutions, across estimator types seem to indicate that the PL estimators underestimate the width
of the confidence interval for the parameters. Taken together these two sets of results strongly
suggest that stratification by institution size in addition to using maximum likelihood is useful for
promoting both precision in the variance estimates and precision in the confidence intervals for
these estimates.
The results of the relative efficiencies seem to correspond to the relationship between the stan-
dard errors as seen in table 4.2. That is the standard errors are consistently smaller for MSPL than
ML while the standard errors for RSPL are larger than ML for one of the strata (200+). Given that
ML is more reliable than PL this would seem to suggest that besides the parameter estimates being
biased for PL that the confidence limits are biased as well. For MSPL for this data the confidence
intervals would be too narrow regardless of strata, while the bias seems to be highly variable, both
too wide and too narrow, for RSPL.
With respect to whether jackknifing would improve the PL estimates in some fashion it seems
that the answer is, partially. As far as parameter estimate bias it does seem to reduce the difference
(for the pooled estimates) between the ML and PL estimates. It also seems that the jackknifing
procedure has the effect of increasing the standard errors for both types of PL. While this is a good
thing for the MSPL standard error estimates it increases the bias for RSPL. It should be noted that
the D-efficiencies are actually slightly lower than the A-efficiencies (as would be expected) but the
difference is out at the third decimal.
These results overall strengthen the argument that ML should be used whenever possible when
using a LNMM and also highlight that stratification should be considered when analyzing SEER-
Medicare data.
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5 SUMMARY AND CONCLUSION
In the last three chapters we have looked at: creating a quality metric based on a logistic
normal model that characterizes adopter type, quantifing the adoption of innovation by institutions
and regions by use of the area under the curve, and considered the effect of estimator type on
the random effect variance components of the model. Here we recap the findings of chapters two
through four as well as suggest some implications of these findings.
In chapter two we considered whether the proposed logistic normal model with hospital level
random effects of a polynomial of time fit the data any better than models previously used in
studies of the diffusion of SLNB. We also considered whether the trajectories based upon this
model could be used as the basis of a metric that characterized adopter of innovation type. For
both of these questions the answer is yes. As demonstrated by the forward model fitting process,
which essentially recapitulated the type of models used over time, it was found that the random
effects model fit the data better and that hospital level random effects of a cubic of time fit the data
best among those models considered. It was also found that this model differentiated between:
regions, hospital within regions, and covariates of interest, thus potentially could be used as the
basis for a metric that measured adopter type.
Additionally, for those interested in more fully understanding the impact of the variables of
interest, treating time as a continuous variable permits the simple examination, via a single inter-
action effect, of changes over time in the magnitude of the effect of a factor associated with the
use of SLNB. For example, it was found that the magnitude of the effect of ACOSOG membership
diminished over time. At the beginning of the time period examined in the analysis the effect of
ACOSOG was rather large, being a ACOSOG member was strongly associated with greater rate
of use of SLNB early in it’s adoption period. Towards the end of the time period examined that
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effect had diminished substantially. Likewise, there was some evidence (p=0.076) that teaching
hospital affiliation had it’s somewhat smaller effect completely disappear by the end of the study
period. Being a member of one of the four cooperative groups considered had a slightly smaller
effect than ACOSOG at the beginning but ended up having a larger effect at the end. Although, it’s
effect possibly (p=0.060) saw some attenuation.
In chapter three, building upon the logistic normal model developed in chapter two, a simple
metric was proposed to quantify adopter type, the area under the curve of the trajectories generated
by the logistic normal model. We called this metric the evidence based medicine implementation
index (EMII). Using a logistic normal model that did not include hospital characteristics, the EMII
was calculated for each hospital. To verify that the EMII of the hospitals did in fact differentiate
between the categories of hospital characteristics, an additional model that used the EMII as the
outcome and hospital characteristics as the independent variables showed that the EMII did vary
consistently by hospital characteristic.
In chapter four we looked at whether the type of estimator of the random effect variance com-
ponent affected either the parameter estimates or the estimate of the uncertainty of the parameter
estimates (the asymptotic covariance matrix). Maximum likelihood was used as the reference es-
timator type against which several forms of pseudo-likelihood based estimators were compared.
When looking at different sizes of hospitals it was found that the number of hospitals in the strata
was associated with considerable variation in the standard error of the RSPL estimator. This sug-
gests that a varying amount of bias in the standard errors of the variance parameter estimates is
present for RSPL in comparison to maximum likelihood. For MSPL the bias was consistently in
the direction of too narrow a confidence interval. This supports the preference of using maximum
likelihood based estimation instead of pseudo-likelihood when possible.
One additional aspect of the data that was discovered, but not discussed in chapter four, is that
the magnitude (and even significance) of the fixed effects seem to vary with the hospital size strata.
For those interested in policy this might be an interesting aspect to explore. Previous work has
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looked at the effect of hospital size with mixed results, but only the main effect and in some papers
it was not found to be significant. The different fixed effect parameter values over the strata of
hospital size would indicate that the interaction of hospital size with the other factors of interest
should be considered.
Other possibilities for further research include: modeling other procedures whose adoption is
of interest, investigating creation of a composite metric that is based upon multiple procedures,
looking at whether the EMII, in conjunction with other quality indicators, predicts outcomes, pa-
tient satisfaction, or costs, and methodological topics such as the use of distributions other than




Here is an overview of the data. Additional background material describing the structure of the
SEER-Medicare database and the variables in each file can be found on the SEER-Medicare web
site: http://healthcaredelivery.cancer.gov/seermedicare/
Contained in Patient Entitlement and Diagnosis Summary File (PEDSF)
SEER Region
Reporting Source





Eligibility data by month including HMO and medicaid status
Demographics from SEER registries
Demographics from CMS
Medicare data files
Hospital inpatient stay file (MEDPAR) - one record per hospital stay
Hospital outpatient claims file (OUTSAF) - one record per billable item
Non-hospital provider claims file (NCH) - one record per billable item
Durable Medical Equipment file (DME) - includes cancer medications
Hospital data (HOSPITAL) provided by NCI for 1996, 1998, and 2000 to 2006
Healthcare cost report data (HCRIS)
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Provider of Service data (POS)
Affiliations in 2002 and 2005
Derived variables:
Time is a scaled zero to one function of diagnosis month and the time span covered by this
study.
Indicator variable for receipt of SLNB based on claims data and SEER registry data
Claims from OUTSAF and NCH files
From diagnosis month to 30 days post first surgery date
HCPCS codes of 38792 or 78195.
SEER variables used depended on year of diagnosis
1999 to 2002 SLNB was identified by a 1 or a 3 value of the variable sxscop1
2003 to 2007 a 2, 6, or 7 value of the sxscof1 variable indicated SLNB
Surgery type (BCS, Mastectomy, both) obtained from MEDPAR and OUTSAF claims
Hospital level variables for institution where first definitive surgery performed
Teaching hospital
NCI designated cancer center in 2002
Member of Cooperative group in 2002 (SWOG, CALGB, NSABP, or ECOG)
Member of ACOSOG 2002
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A.2 Calculating Area Under the Curve in Chapter three
The AUC was calculated by use of an approximation that calculated the probability of receipt
of SLNB for each of the 108 months in the study (using the midpoint). These probabilities were
a function of the fixed effects plus (for individual hospitals) the best linear unbiased predictors.
These probabilities were then summed and divided by 108. SAS macro is available upon request.
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